EP2028938A1 - 3,4-disubstituted coumarin and quinolone compounds - Google Patents

3,4-disubstituted coumarin and quinolone compounds

Info

Publication number
EP2028938A1
EP2028938A1 EP06759899A EP06759899A EP2028938A1 EP 2028938 A1 EP2028938 A1 EP 2028938A1 EP 06759899 A EP06759899 A EP 06759899A EP 06759899 A EP06759899 A EP 06759899A EP 2028938 A1 EP2028938 A1 EP 2028938A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06759899A
Other languages
German (de)
French (fr)
Other versions
EP2028938A4 (en
Inventor
Bin Xu
Qiang Zhu
Hyun-Joon Cho
Reza Fathi
Zhen Yang
Anthony Sandrasagra
Yixin Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XTL Biopharmaceuticals Ltd
Original Assignee
XTL Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XTL Biopharmaceuticals Ltd filed Critical XTL Biopharmaceuticals Ltd
Publication of EP2028938A1 publication Critical patent/EP2028938A1/en
Publication of EP2028938A4 publication Critical patent/EP2028938A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to 3,4-disubstituted coumarin and quinolone derivatives and processes for their preparation.
  • the invention also related to methods for treating infection of Hepatitis C virus by administering a 3,4-disubstituted coumarin or quinolone derivative.
  • the invention provides a synthetic process for the preparation of 3,4-disubstituted coumarin and quinolone derivatives using mild reaction conditions, which provides a high substituent tolerance and is appropriate for use in solid phase syntheses for producing a library of 3,4-disubstituted coumarin and quinolone derivatives for biological screening.
  • HCV Hepatitis C virus
  • the present invention provides 3,4-disubstituted coumarin and quinolone derivatives having the formula I
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR 11 , -N(R 12 XR 13 ), -N(R 1 ⁇ C(O)R 11 , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 )(R 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substiruents
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom;
  • R 34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
  • X is selected from O and N-R 4 ;
  • R 4 is selected from the group consisting of H 5 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 41 , -(CH 2 ) ⁇ C(O)N(R 42 )(R 43 ), -(CH 2 ) ⁇ C(O)OR 41 , and -(CH 2 )AO)N(R 42 XR 43 ), each R 41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • the alkyl group may be optionally substituted with one or more substituents selected from halo, CN, NO 2 , CO 2 R, C(O)R, -O-R, -N(R 1 XR"). -N(R)C(O)R, -N(R)SO 2 R, -SR, -C(O)N(RO(R"), -OC(O)R, -OC(O)N(R 1 XR"), SO 2 , -SOR, -SO 3 R, -SO 2 N(R 1 XR"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halo, CN, NO 2 , CO 2 R, C(O)R, -O-R, -N(R 1 XR").
  • alkynyl as used herein contemplates substituted or unsubstituted, straight and branched carbon chain containing from two to 8 carbon atoms and having at least one carbon-carbon triple bond.
  • alkynyl includes, for example ethynyl, 1-propynyl, 2- propynyl, 1-butynyl, 3 -methyl- 1-butynyl, and the like.
  • the alkynyl group maybe optionally substituted with one or more substituents selected from halo, CN, NO 2 , CO 2 R, C(O)R, -O-R, -N(RO(R"), -N(R)C(O)R, -N(R)SO 2 R, -SR, -C(O)N(RO(R"), -OC(O)R, -OC(O)N(RO(R"), SO 2 , -SOR, -SO 3 R 5 -SO 2 N(RO(R"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halo, CN, NO 2 , CO 2 R, C(O)R, -O-R, -N(RO(R"), -N(R)C(O)R, -N(R)SO 2 R, -SR, -C(O)N(RO(
  • cycloalkyl as used herein contemplates substituted or unsubstituted cyclic alkyl radicals containing form 3 to 7 carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • the cycloalkyl group may be optionally substituted with one or more substituents selected from halo, CN, NO 2 , CO 2 R, C(O)R, -O-R, -N(RO(R"), -N(R)C(O)R, -N(R)SO 2 R, -SR, -C(O)N(RO(R"), -OC(O)R, -OC(O)N(RO(R"), SO 2 , -SOR, -SO 3 R, -SO 2 N(R')(R"), phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halo, CN, NO 2 , CO 2 R, C(O)R, -O-R, -N(RO(R"), -N(R)C(O)R, -N(R)SO 2 R, -SR, -C(O)N(RO
  • cycloalkenyl as used herein contemplates substituted or unsubstituted cyclic alkenyl radicals containing form 5 to 7 carbon atoms in which has a double bond between two of the ring carbons and includes cyclopentenyl, cyclohexenyl, and the like.
  • Aromatic heterocyclic groups also termed "heteroaryl” groups contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.
  • heteroaryl also includes polycyclic hetero- aromatic systems having two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls.
  • polycyclic heteroaromatic systems include quinoline, isoquinoline, tetrahydroisoquinoline, quinoxaline, quinaxoline, benzimidazole, benzofuran, purine, imidazopyridine, benzotriazole, and the like.
  • the heterocyclic group may be optionally substituted with one or more substituents selected from halo, alkyl, CN, NO 2 , CO 2 R 5 C(O)R, -0-R, -N(R')(R"), -N(R)C(O)R, -N(R)SO 2 R, -SR, -C(O)N(R')(R"), -OC(O)R, -OC(O)N(R 1 XR"), SO 2 , -SOR, -SO 3 R, -SO 2 N(R')(R"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halo, alkyl, CN, NO 2 , CO 2 R 5 C(O)R, -0-R, -N(R')(R"), -N(R)C(O)R, -N(R)SO 2 R
  • aryl as used herein contemplates substituted or unsubstituted single-ring aromatic groups (for example, phenyl, pyridyl, pyrazole, etc.) and polycyclic ring systems (naphthyl, quinoline, etc.).
  • the polycyclic rings may have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls.
  • Each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl.
  • Each R 1 and R" are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 1 and R" may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom.
  • R 2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom
  • R 34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
  • R 4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 41 , -(CH 2 ) ⁇ C(O)N(R 42 )(R 43 ), -(CH 2 ) ⁇ C(O)OR 41 , and -(CH 2 ) ⁇ C(O)N(R 42 XR 43 ), each R 41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 42 and R 43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 42 and R 43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further /heteroatom; b is O to 6; Y is selected from O and N-R 5 ;
  • R 5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 51 , -(CH 2 ) ⁇ C(O)N(R 52 )(R 53 ), and -(CH 2 ) ⁇ C(O)OR 51 ; each R 51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 52 and R 53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
  • the substances according to the invention may be present as salts. In the context of the invention, preference is given to pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts refers to an acid addition salt or a basic addition salt of a compound of the invention in which the resulting counter ion is understood in the art to be generally acceptable for pharmaceutical uses.
  • Pharmaceutically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids.
  • salts with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid
  • organic carboxylic or sulfonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.
  • Pharmaceutically acceptable salts can also be metal or ammonium salts of the compounds according to the invention.
  • each R 1 group may be selected independently.
  • the R 1 groups may be selected from any of the stated groups so as to be the same or different. This also holds true for any other group or substituent which may be selected independently from among various groups or values.
  • R 2 is selected from aryl and aralkyl.
  • Y is selected to be a O to give a compound of the formula II:
  • R 2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl
  • X is selected from O and N-R 4 ;
  • X of a compound according to formula II is selected to be a O to give a compound of the formula III:
  • R 2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R l , -N(R 12 )(R 13 ), -N(R ⁇ )C(O)R ⁇ , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substituent
  • R 7 is selected from the group consisting of aryl, heteroaryl, -C(O)R 31 , -C(O)N(R 32 )(R 33 ), -C(O)OR 31 , -C(O)N(R 32 XR 33 ), and -N(R 32 )(R 33 ),
  • R selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R 11 , -N(R 12 )(R 13 ), -N(R 1 ⁇ C(O)R 11 , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substituents on
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 6 and R 7 of a compound according to formula IV are selected to be phenyl groups, to give a compound of the formula VI:
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R 11 , -N(R 12 )(R 13 ), -N(R ⁇ )C(O)R n , -N(R u )SO 2 R ⁇ , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R u , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) h C(O)R 41 , -(CH 2 )iC(O)N(R 42 )(R 43 ), -(CH 2 ) ⁇ C(O)OR 41 , and -(CH 2 ) ⁇ C(O)N(R 42 )(R 43 ), each R 41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R 42 and R 43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R 3 may be taken together with the nitrogen to which they are
  • R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl;
  • R 4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 41 , -(CH 2 ) ⁇ C(O)N(R 42 XR 43 ), -(CH 2 ) ⁇ C(O)OR 41 , and -(CH 2 ) 6 C(O)N(R 42 )(R 43 ), each R is- independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 42 and R 43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; & is O to 6; and R 34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or a pharmaceutically acceptable salt or hydrate thereof.
  • R 2 is selected to be an aryl or heteroaryl groups.
  • R 4 is H.
  • R 42 and R 43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 42 and R 43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
  • R 6 is selected from the group consisting of aryl and heteroaryl
  • R 7 is selected from the group consisting of aryl, heteroaryl, -C(O)R 31 , -C(O)N(R 32 )(R 33 ), -C(O)OR 31 , -C(O)N(R 32 XR 33 ), and -N(R 32 )(R 33 ),
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
  • R 7 is selected to be an aryl or heteroaryl groups.
  • R is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 31 , -(CH 2 ) ⁇ C(O)N(R 32 )(R 33 ), (CH 2 ) ⁇ C(O)OR 31 , -(CH 2 ) ⁇ C(O)N(R 32 )(R 33 ), -(CH 2 ) ⁇ N(R 32 )(R 33 ), -CH-N-R 34 ,
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom;
  • R 34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
  • R 4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 41 , -(CH 2 ) ⁇ C(O)N(R 42 )(R 43 ), -(CH 2 ) ⁇ C(O)OR 41 , and -(CH 2 ) 6 C(O)N(R 42 )(R 43 ), .
  • each R 41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 6 and R 7 of a compound according to formula VIII are selected to be phenyl groups, to give a compound of the formula X:
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR 11 , -N(R 12 XR 13 ), -N(R 1 ⁇ C(O)R 11 , -N(R 11 JSO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, phosphate, phosphonate, halo, aryl and heteroaryl; additionally or alternatively two R substituents on adjacent ring atom
  • R 42 and R 43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 42 and R 43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO 2 , CO 2 R , C(O)R 81 , -0-R 81 , -N(R 82 )(R 83 ), -N(R 81 )C(O)R 81 , -N(R 81 )SO 2 R 81 , -SR 81 , -C(O)N(R 82 )(R 83 ), -OC(O)R 81 , -OC(O)N(R 82
  • Y is selected to be a N-R 5 to give a compound of the formula XI:
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R 11 , -N(R 12 )(R 13 ), -N(R 1 ⁇ C(O)R 11 , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substituents on adjacent
  • R 2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom;
  • R 3 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
  • X is selected from O and N-R 4 ;
  • R 42 and R 43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 42 and R 43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
  • R is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 51 , -(CH 2 )iC(O)N(R 52 )(R 53 ), and -(CH 2 ) ⁇ C(O)OR 51 ; each R 51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 52 and R 53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
  • X of a compound according to formula XI is selected to be a O to give a compound of the formula XII: wherein: each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R 11 , -N(R 12 )(R 13 ), -N(R n )C(O)R n , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 ,
  • R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl;
  • R 3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) a C(O)R 31 , -(CH 2 ) fl C(O)N(R 32 )(R 33 ), (CH 2 ) fl C(O)OR 31 , -(CH 2 ) ⁇ C(O)N(R 32 )(R 33 ), -(CH 2 ) fl N(R 32 )(R 33 ), -CH-N-R 34 ,
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R aanndd RR 33 aarree independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom;
  • R 34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
  • R 5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 51 , -(CH 2 ) 6 C(O)N(R 52 )(R 53 ), and -(CH 2 ) ⁇ C(O)OR 51 ; each R 51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R 52 and R 53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and
  • R 2 and R 3 of a compound according to formula XII are selected to be a -CH 2 -R 6 and -CH 2 -R 7 , respectively, to give a compound of the formula XIII:
  • R 5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 51 , -(CH 2 ) 6 C(O)N(R 52 )(R 53 ), and -(CH 2 ) ⁇ C(O)OR 51 ; each R 51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 52 and R 53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
  • R 7 is selected from the group consisting of aryl, heteroaryl, -C(O)R 31 , -C(O)N(R 32 )(R 33 ), -C(O)OR 31 , -C(O)N(R 32 XR 33 ), and -N(R 32 )(R 33 ),
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
  • R 6 is selected to be an aryl or heteroaryl groups.
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R 11 , -N(R 12 XR 13 ), -N(R 1 ⁇ C(O)R 11 , -N(R n )SO 2 R n , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
  • R is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 51 , -(CH 2 ) ⁇ C(O)N(R 52 )(R 53 ), and -(CH 2 ) ⁇ C(O)OR 51 ; each R 51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO 2 , CO 2 R , C(O)R 81 , -0-R 81 , -N(R 82 XR 83 ), -N(R 8 ⁇ C(O)R 81 , -N(R 81 )SO 2 R 81 , -SR 81 , -C(O)N(R 82 )(R 83 ), -OC(O)R 81 , -OC(O)N(R 82 O(R 83 ), SO 2
  • R 6 and R 7 of a compound according to formula XIII are selected to be phenyl groups, to give a compound of the formula XV:
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R 11 , -N(R 12 XR 13 ), -N(R n )C(O)R n , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substituents
  • R 52 and R 53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO 2 , CO 2 R , C(O)R 81 , -0-R 81 , -N(R 82 XR 83 ), -N(R 81 )C(O)R 81 , -N(R 81 )SO 2 R 81 , -SR 81 , -C(O)N(R 82 )(R 83 ), -OC(O)R 81 , -OC(O)N(R 82t )(R 83
  • X of a compound according to formula XI is selected to be a N-R 4 to give a compound of the formula XVI:
  • each R is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R l , -N(R 12 )(R 13 ), -N(R 1 ⁇ C(O)R 11 , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substituents on
  • R 2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom;
  • R 34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
  • R 52 and R 53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R , -N(R 12 XR 13 ), -N(R n )C(O)R ⁇ , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substituents on
  • R 4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 41 , -(CH 2 ) ⁇ C(O)N(R 42 )(R 43 ), -(CH 2 ) ⁇ C(O)OR 41 , and -(CH 2 ) ⁇ C(O)N(R 42 )(R 43 ), each R 41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 51 , -(CH 2 ) ⁇ C(O)N(R 52 )(R 53 ), and -(CH 2 ) ⁇ C(O)OR 51 ; each R 51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 52 and R 53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; & is O to 6;
  • R 6 is selected from the group consisting of aryl and heteroaryl
  • R 7 is selected from the group consisting of aryl, heteroaryl, -C(O)R 31 , -C(O)N(R 32 )(R 33 ), -C(O)OR 31 , -C(O)N(R 32 XR 33 ), and -N(R 32 )(R 33 ),
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR 11 , -N(R 12 )(R 13 ), -N(R 1 ⁇ C(O)R 11 , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(0)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substituents
  • R 31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 32 and R 33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom;
  • R 34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
  • R 4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 41 , -(CH 2 ) 6 C(O)N(R 42 )(R 43 ), -(CH 2 ) ⁇ C(O)OR 41 , and -(CH 2 ) 6 C(O)N(R 42 )(R 43 ), each R 41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R ' aanndd RR 53 aarree iinnddeeppeennddeennttllyy sseelleecctteedd frfroomm HH,, aallkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO 2 , CO 2 R , C(O)R 81 , -0-R 81 , -N(R 82 XR 83 ), -N(R 81 )C(O)R 81 , -N(R 81 )SO 2 R 81 , -SR 81 , -C(O
  • R and R 7 of a compound according to formula XVII are selected to be phenyl groups, to give a compound of the formula XIX:
  • each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R 11 , -N(R 12 XR 13 ), -N(R n )C(0)R ⁇ , -N(R 1 ⁇ SO 2 R 11 , -SR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 12 XR 13 ), -OC(O)R 11 , -OC(O)N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , -SOR 11 , -SO 3 R 11 , -SO 2 N(R 12 XR 13 ), -alkyl-O-R 11 , cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R 1 substituents on adjacent
  • R 4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 41 , -(CH 2 ) ⁇ C(O)N(R 42 )(R 43 ), -(CH 2 ) ⁇ C(O)OR 41 , and -(CH 2 ) ⁇ C(O)N(R 42 XR 43 ), each R 41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R 5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH 2 ) ⁇ C(O)R 51 , -(CH 2 )iC(O)N(R 52 )(R 53 ), and -(CH 2 ) ⁇ C(O)OR 51 ; each R 51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
  • R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 52 and R 53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO 2 , CO 2 R , C(O)R 81 , -0-R 81 , -N(R 82 XR 83 ), -N(R 81 )C(O)R 81 , -N(R 81 )SO 2 R 81 , -SR 81 , -C(O)N(R 82 )(R 83 ), -OC(O)R 81 , -OC(O)N(R 82 ')(R 83
  • salts with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid
  • organic carboxylic or sulfonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.
  • Pharmaceutically acceptable salts can also be metal or ammonium salts of the compounds according to the invention.
  • ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine.
  • ammonia or organic amines such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine.
  • each R 1 group may be selected independently.
  • the R 1 groups may be selected from any of the stated groups so as to be the same or different. This also holds true for any other group or substituent which may be selected independently from among various groups or values.
  • a 1 and A 2 may be treated with an alcohol (HO-R 2 ) or amine (H 2 N-R 2 ) in the presence of an appropriate base.
  • LG represents a leaving group, such as halo, aryl sulfones (tosyl, etc.), triflate or other appropriate leaving group as would be recognized by the ordinarily skilled practitioner.
  • the base may be selected from amine bases, hydroxide salts (non-limiting examples include sodium hydroxide and tetraalkylamonium hydroxides), carbonate salts, hydrides, alkoxide salts (non-limiting examples include sodium methoxide and potassium t- butoxide) and the like.
  • protecting group means temporary modifications of a potentially reactive functional group which protect it from undesired chemical transformations.
  • protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively.
  • the field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2 nd ed.; Wiley: New York, 1991).
  • the compounds and processes disclosed herein are useful in the production of a library of 3,4-disubstituted coumarin and quinolone derivatives for biological screening.
  • Derivatives of coumarin and quinolone posses a range of biological activities.
  • Coumarin-based and quinolone-based compounds have shown efficacy, for example, as antivirals.
  • the compounds of the present invention may be used to prevent or treat infection with HCV.
  • HCV Replicon Assay developed in the laboratories of Bartenschlager (Lohman et al, Science 285, 110-113, 1999) and Rice (Blight et al, Science 290, 1972-1974, 2000).
  • the assay is performed using the Huh-Luc- Neo cell line (Lohman et al, Science 285, 110-113, 1999).
  • Huh-Luc- Neo cells are a human hepatoma cell line (Huh-7) stably expressing a bi-cistronic subgenomic replicon containing the HCV IRES in which the structural proteins of HCV had been deleted and replaced by a construct containing sequences coding for the firefly luciferase reporter gene, the neomycin selectable marker and the EMCV IRES to direct expression of a truncated HCV genome expressing the structural proteins NS3, NS4A, NS4B, NS5A, and NS5B.
  • HCV targets through which inhibitors could act to inhibit replication include the NS3 protease, the helicase/ATPase, NS5A, the NS5B- RNA dependent RNA polymerase, and the HCV IRES.
  • HCV IRES driven luciferase reporter activity and HCV RNA is measured to obtain indirect and direct measures of replication of HCV RNA respectively.
  • Inhibitors of HCV replication and/or proliferation are determined by initially identifying molecules that inhibit expression of the HCV IRES driven luciferase reporter in this HCV Replicon Luciferase Assay. Cell viability assays and control cell based luciferase assays are then run on hits identified in the HCV Replicon Luciferase Assay to eliminate cytoxic compounds and non-specific compounds which act by inhibiting the luciferase enzyme.
  • HCV Replicon Luciferase hits that are specific and non-cytoxic and demonstrating that these compounds inhibit expression of HCV RNA using a quantitative PCR based approach (Taqman) using primers and probes specific for HCV RNA (HCV Replicon RNA Assay).
  • the HCV Replicon Assay may be used to predict compound efficacy in treatment and/or prevention of HCV infection as well as inhibition of HCV replication and/or proliferation.
  • the HCV Replicon encompasses a multiplicity of viral and host targets through which an inhibitor could work to inhibit HCV Replication.
  • Viral targets expressed in the HCV Replicon include the HCV IRES (for translation), NS3 Protease, the HCV Helicase/ATPase, NS5A phosphorylation, and the NS5B polymerase.
  • HCV IRES for translation
  • NS3 Protease for translation
  • the HCV Helicase/ATPase HCV Helicase/ATPase
  • NS5A phosphorylation NS5B polymerase
  • the present invention provides pharmaceutical compositions comprising an anti-HCV effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, in combination with a pharmaceutically acceptable carrier or auxiliary agent.
  • pharmaceutically acceptable salts and “hydrates” refer to those salts and hydrated forms of the compound that would favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion.
  • Other factors, more practical in nature, which those skilled in the art may take into account in the selection include the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug.
  • the compounds of the invention may be administered alone or may be administered in combination with other approved therapeutics, such as: an interferon (pegylated or not), preferably ⁇ -interferon, ribavirin, or interferon and ribavirin, or one or more other anti-HCV agent, such as an HCV protease inhibitor, HCV polymerase inhibitor, HCV IRES inhibitor, HCV Helicase and/or ATPase inhibitor, NS5A phosphorylation inhibitor, HCV NS2 inhibitor, or other HCV life cycle inhibitor.
  • Combination therapies with may include a compound of the invention with multiple different inhibitors of HCV life cycle (immunomodulatory agents, Toll Like Receptor modulators, antisense therapeutics etc.).
  • the agents that comprise a combination therapy may be administered together or separately, e.g., prior to, concurrently with or following the administration of the compound of the invention or pharmaceutically acceptable salt thereof.
  • additional agents may be combined with the compounds of this invention to create a single pharmaceutical dosage form.
  • these additional agents may be separately administered to the patient as- part of a multiple dosage form, for example, using a kit.
  • Such additional agents may be administered to the patient prior to, concurrently with, or following the administration of wherein a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the compounds of the present invention may be employed in solid or liquid form including, for example, amorphous powder or crystalline form, in solution or in suspension. They may be administered in numerous different ways, such as orally, parenterally, topically, transdermally or by inhalation. Oral administration or administration by injection is preferred.
  • the choice of carrier and the content of active compound in the carrier are generally determined in accordance with the solubility and chemical properties of the desired product, the particular mode of administration and well established pharmaceutical practice.
  • the pharmaceutical composition of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, and intralesional injection or infusion techniques.
  • Injectable forms must be fluid to the extent they can be easily syringed, and proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • the pharmaceutical composition maybe in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example Tween 80) and suspending agents.
  • the pharmaceutical composition of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions.
  • Compounds of the invention may be enclosed in hard or soft shell gelatin capsules, or compressed into tablets.
  • oral liquid dosage forms include solutions, suspensions, syrups, emulsions, soft gelatin capsules and the like.
  • Carriers for oral use may include time delay materials known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
  • lactose and a liquid carrier such as high molecular weight polyethylene glycols.
  • Diluents such as sucrose, ethanol, polyols such as polyethylene glycol, propylene glycol and glycerol, and mixtures thereof also may be used.
  • the active compound may be incorporated into sustained-release preparations and formulations. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
  • suitable vehicles or carriers for the above noted formulations and compositions can be found in standard pharmaceutical texts, e.g. in "Remington's Pharmaceutical Sciences", The Science and Practice of Pharmacy, 19.sup.th Ed. Mack Publishing Company, Easton, Pa., (1995).
  • the resulting composition may be administered in vivo to mammals, such as man, to treat or prevent HCV virus infection.
  • mammals such as man
  • Such treatment may also be achieved using a compound of this invention in combination with other anti- viral agents which include, but are not limited to a-interferon and ribavirin.
  • the additional agents may be combined with compounds of this invention to create a single dosage form. Alternatively these additional agents may be separately administered to a mammal as part of a multiple dosage form.
  • reaction solvents were commercially purchased from Acros and Aldrich without further purification and reagents were used as received. Reactions for the synthesis of the starting material were monitored by thin-layer chromatography (TLC) on 0.25 mm precoated Merck Silica Gel 60 F 254 , visualizing with ultraviolet light or phosphomolybdic acid stain. Flash column chromatography was performed on Merck Silica Gel 60 (230-400 mesh) using reagent grade hexanes, dichloromethane, methanol and ethyl acetate. [0075] Reaction reagents were commercially purchased from Alrich and used as received.
  • Huh-Luc-Neo Cells are seeded at 25,000/well in an opaque-walled 96 plate with Growth Medium (DMEM phenol red free + PS + 2mM glutamine; 100 ⁇ l/well).
  • the compounds to be tested are added to the experimental wells (10 ⁇ l/well at 1OX assay concentration) and the cells are then incubated (5% CO 2 , 37 0 C) for 48h.
  • Bright-Glo Luciferase Assay reagent Bright-Glo Luciferase Assay Buffer + Bright-Glo Luciferase Assay Substrate Mixture
  • the well contents are mixed for 5 min. on an orbital shaker at room temperature to induce cell lysis and the luminescence is then measured using a luminometer.
  • the data is analyzed and IC50s are determined using GraphPad Prism 4 software.
  • Hits validated in the Replicon Luciferase assay have IC50s ⁇ 8.0 ⁇ M and show ⁇ 30% inhibition of Cell Viability at a compound concentration of 100 ⁇ M (Cell Titer Glow Assay, cell viability assay conditions identical to HCV Replicon Luciferase Assay conditions).
  • Huh-Luc-Neo Cells are seeded at 25,000/well in an opaque-walled 96 plate with Growth Medium (DMEM phenol red free + PS + 2mM glutamine; 100 ⁇ l/well).
  • the compounds to be tested are added to the experimental wells (10 ⁇ l/well at 1OX assay concentration) and the cells are then incubated (5% CO 2 , 37 0 C).
  • RNA Isolation and cDNA Synthesis The cells are washed with IX Phosphate Buffered Saline (PBS) once. Cells are then lysed and RNA is isolated in 96 well format using a vacuum manifold and the RNAeasy 96 kit (Qiagen) according to the manufacturer's suggested protocol. cDNA is then synthesized from RNA isolated from each well using the Taqman Reverse Transcription Reagents kit (Applied Biosystems) according to manufacturer's suggested protocol.
  • PBS IX Phosphate Buffered Saline
  • Huh-Luc-Neo Cells are seeded at 25,000/well in an opaque-walled 96 plate with Growth Medium (DMEM phenol red free + PS + 2mM glutamine; lOOul/well).
  • the compounds to be tested for inhibition of cell viability are added to the experimental wells (10 ⁇ l/well at 1OX assay concentration) and the cells are then incubated (5% CO 2 , 37 0 C) for 48h.
  • VQ_33645 2.33 21.5 >30 17.2
  • VQ_34453 8.5 24.6 1.97 12.2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to 3,4-disubstituted coumarin and quinolone derivatives and processes for their preparation. The invention also related to methods for treating infection of Hepatitis C virus by administering a 3,4-disubstituted coumarin or quinolone derivative.

Description

3,4-DISUBSTITUTED COUMARIN AND QUINOLONE COMPOUNDS
FIELD OF THE INVENTION
[0001] The present invention relates to 3,4-disubstituted coumarin and quinolone derivatives and processes for their preparation. The invention also related to methods for treating infection of Hepatitis C virus by administering a 3,4-disubstituted coumarin or quinolone derivative. The invention provides a synthetic process for the preparation of 3,4-disubstituted coumarin and quinolone derivatives using mild reaction conditions, which provides a high substituent tolerance and is appropriate for use in solid phase syntheses for producing a library of 3,4-disubstituted coumarin and quinolone derivatives for biological screening.
BACKGROUND OF THE INVENTION
[0002] Strategies in new drug discovery often look to natural products for leads in finding new chemical compounds with therapeutic properties. One of the recurring problems in drug discovery is the availability of organic compounds derived from natural sources. Techniques employing combinatorial chemistry attempt to overcome this problem by allowing the high throughput synthesis and testing of hundreds or thousands of related synthetic compounds, called a chemical library, hi designing the synthesis of a prospective therapeutic compound or a chemical library, one often looks to natural chemical motifs which are known to have broad biological activity. Coumarin and Quinolone derivatives are of particular interest due to their frequent occurrence in nature and range of biological activities.
[0003] Coumarins are widely distributed in the plant kingdom. Approximately 50 naturally occurring coumarin derivatives have been identified. Derivatives of both coumarin and quinolone posses a range of biological activities. To avoid confusion, the coumarin and quinolone derivatives described herein are numbered according to the following convention:
[0004] Infection with the Hepatitis C virus (HCV) represents a serious world-wide health crisis. In more than 70% of infected individuals, the virus evades clearance by the immune system leading to a persistent HCV infection. The long term effects of persistent HCV infection range from an apparently healthy carrier state to chronic hepatitis, liver fibrosis, cirrhosis, and eventually hepatocellular carcinoma. HCV is a leading cause of chronic liver disease. The best therapy currently available for treatment of HCV infection uses a combination of pegylated α- interferon and ribavirin. However, many of the patients treated with this therapy fail to show a sufficient antiviral response. Additionally, interferon treatment also induces severe side-effects (i.e. retinopathy, thyroiditis, acute pancreatitis, depression) that diminish the quality of life of treated patients. Thus, it is vital that more effective treatments be identified.
SUMMARY OF THE INVENTION
[0005] The present invention provides 3,4-disubstituted coumarin and quinolone derivatives having the formula I
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12XR13), -N(R1^C(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12)(R13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substiruents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R ; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)flC(O)R31, -(CH2)αC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)flN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
X is selected from O and N-R4;
R4 is selected from the group consisting of H5 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)έC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)AO)N(R42XR43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; Y is selected from O and N-R5;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)AC(O)R51, -(CH2)6C(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and
& is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
[0006] The invention also provides a synthetic process for the preparation of compounds of the formula I. The process uses mild reaction conditions, which provides a high substituent tolerance. Thus, the process is applicable to the preparation of a wide variety of 3,4-disubstituted coumarin and quinolone derivatives with diverse substitution patterns. Additionally, the process is appropriate for use with combinatorial synthesis techniques. Thus, the process provides a method for producing a library of 3,4-disubstituted coumarin and quinolone derivatives for biological screening.
[0007] The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention in a therapeutically effective amount.
DETAILED DESCRIPTION OF THE INVENTION
[0008] The term "halo" or "halogen" as used herein includes fluorine, chlorine, bromine and iodine. [0009] The term "alkyl" as used herein contemplates substituted or unsubstituted, straight and branched chain alkyl radicals containing from one to fifteen carbon atoms. The term "lower alkyl" as used herein contemplates both straight and branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl, and the like. The alkyl group may be optionally substituted with one or more substituents selected from halo, CN, NO2, CO2R, C(O)R, -O-R, -N(R1XR"). -N(R)C(O)R, -N(R)SO2R, -SR, -C(O)N(RO(R"), -OC(O)R, -OC(O)N(R1XR"), SO2, -SOR, -SO3R, -SO2N(R1XR"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0010] The term "alkenyl" as used herein contemplates substituted or unsubstituted, straight and branched chain alkene radicals containing from two to 8 carbon atoms. The alkenyl group may be optionally substituted with one or more substituents selected from halo, CN, NO2, CO2R, C(O)R, -O-R, -N(R')(R"), -N(R)C(O)R, -N(R)SO2R, -SR, -C(O)N(RO(R"), -OC(O)R, -OC(O)N(RO(R"), SO2, -SOR, -SO3R, -SO2N(RO(R"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0011] The term "alkynyl" as used herein contemplates substituted or unsubstituted, straight and branched carbon chain containing from two to 8 carbon atoms and having at least one carbon-carbon triple bond. The term alkynyl includes, for example ethynyl, 1-propynyl, 2- propynyl, 1-butynyl, 3 -methyl- 1-butynyl, and the like. The alkynyl group maybe optionally substituted with one or more substituents selected from halo, CN, NO2, CO2R, C(O)R, -O-R, -N(RO(R"), -N(R)C(O)R, -N(R)SO2R, -SR, -C(O)N(RO(R"), -OC(O)R, -OC(O)N(RO(R"), SO2, -SOR, -SO3R5 -SO2N(RO(R"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0012] The term "cycloalkyl" as used herein contemplates substituted or unsubstituted cyclic alkyl radicals containing form 3 to 7 carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl, and the like. The cycloalkyl group may be optionally substituted with one or more substituents selected from halo, CN, NO2, CO2R, C(O)R, -O-R, -N(RO(R"), -N(R)C(O)R, -N(R)SO2R, -SR, -C(O)N(RO(R"), -OC(O)R, -OC(O)N(RO(R"), SO2, -SOR, -SO3R, -SO2N(R')(R"), phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
[0013] The term "cycloalkenyl" as used herein contemplates substituted or unsubstituted cyclic alkenyl radicals containing form 5 to 7 carbon atoms in which has a double bond between two of the ring carbons and includes cyclopentenyl, cyclohexenyl, and the like. The cycloalkenyl group may be optionally substituted with one or more substituents selected from halo, CN, NO2, CO2R, C(O)R, -0-R, -N(R')(R"), -N(R)C(O)R, -N(R)SO2R, -SR, -C(O)N(R')(R"), -OC(O)R, -OC(O)N(R')(R"), SO2, -SOR, -SO3R, -SO2N(RO(R"), phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
[0014] The term "aralkyl" as used herein contemplates a lower alkyl group which has as a substituent an aromatic group, which aromatic group may be substituted or unsubstituted. The aralkyl group may be optionally substituted with one or more substituents selected from halo, CN, NO2, CO2R, C(O)R, -0-R, -N(RO(R"), -N(R)C(O)R, -N(R)SO2R, -SR, -C(O)N(RO(R"), -OC(O)R, -OC(O)N(RO(R"), SO2, -SOR, -SO3R, -SO2N(RO(R"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0015] The terms phosphate and phosphonate as used herein refer to the moieties having the following structures, respectively:
[0016] The term "heterocyclic group" or "heterocyclic ring" as used herein contemplates substituted or unsubstituted aromatic and non-aromatic cyclic radicals having at least one heteroatom as a ring member. Preferred heterocyclic groups are those containing 5 or 6 ring atoms which includes at least one hetero atom, and includes cyclic amines such as morpholino, piperidino, pyrrolidino, and the like, and cyclic ethers, such as tetrahydrofuran, tetrahydropyran, and the like. Aromatic heterocyclic groups, also termed "heteroaryl" groups contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like. The term heteroaryl also includes polycyclic hetero- aromatic systems having two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls. Examples ofpolycyclic heteroaromatic systems include quinoline, isoquinoline, tetrahydroisoquinoline, quinoxaline, quinaxoline, benzimidazole, benzofuran, purine, imidazopyridine, benzotriazole, and the like. The heterocyclic group may be optionally substituted with one or more substituents selected from halo, alkyl, CN, NO2, CO2R5 C(O)R, -0-R, -N(R')(R"), -N(R)C(O)R, -N(R)SO2R, -SR, -C(O)N(R')(R"), -OC(O)R, -OC(O)N(R1XR"), SO2, -SOR, -SO3R, -SO2N(R')(R"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0017] The terms "aryl", "aromatic group", or "aromatic ring" as used herein contemplates substituted or unsubstituted single-ring aromatic groups (for example, phenyl, pyridyl, pyrazole, etc.) and polycyclic ring systems (naphthyl, quinoline, etc.). The polycyclic rings may have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls. The aryl group may be optionally substituted with one or more substituents selected from halo, alkyl, CN, NO2, CO2R, C(O)R, -0-R, -N(R')(R"), -N(R)C(O)R, -N(R)SO2R, -SR, -C(O)N(R')(R"), -OC(O)R, -OC(O)N(R')(R"), SO2, -SOR, -SO3R, -SO2N(R')(R"), phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0018] Each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl. Each R1 and R" are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R1 and R" may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom.
[0019] The term "heteroatom", particularly as a ring heteroatom, refers to N, O, and S.
[0020] All value ranges, for example those given for n and m, are inclusive over the entire range. Thus, a range of O to 4 would include the values 0, 1, 2, 3 and 4. [0021] The present invention provides compounds of the formula I:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12)(R13), -N(R11)C(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12)(R13), -OC(O)R11, -OC(O)N(R12XR13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12)(R13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)ΩC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
X is selected from O and N-R4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)όC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)^C(O)N(R42XR43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further /heteroatom; b is O to 6; Y is selected from O and N-R5;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)έC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof. [0022] The substances according to the invention may be present as salts. In the context of the invention, preference is given to pharmaceutically acceptable salts. Pharmaceutically acceptable salts refers to an acid addition salt or a basic addition salt of a compound of the invention in which the resulting counter ion is understood in the art to be generally acceptable for pharmaceutical uses. Pharmaceutically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids. Preference is given to salts with inorganic acids, such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or to salts with organic carboxylic or sulfonic acids, such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid. Pharmaceutically acceptable salts can also be metal or ammonium salts of the compounds according to the invention. Particular preference is given to, for example, sodium, potassium, magnesium or calcium salts, and also to ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2- phenylethylamine. (see, Berge et al. J. Pharm. Sd. 1977, 66, 1-19.)
[0023] When one or more chiral centers are present in the compounds of the present invention, the individual isomers and mixtures thereof (e.g., racemates, etc.) are intended to be encompassed by the formulae depicted herein. In certain embodiments, compounds of the invention may exist in several tautomeric forms. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds. Compounds of the invention may exist in various hydrated forms.
[0024] It is understood that when n is a value greater than 1 , each R1 group may be selected independently. Thus, when more than one R1 group is present, the R1 groups may be selected from any of the stated groups so as to be the same or different. This also holds true for any other group or substituent which may be selected independently from among various groups or values.
[0025] In preferred embodiments of the invention, R2 is selected from aryl and aralkyl. [0026] In one embodiment of the invention, Y is selected to be a O to give a compound of the formula II:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(Rn)C(O)Rn, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF35 NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)aC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; a is 0 to 6;
X is selected from O and N-R4;
R is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)έC(O)R41, -(CH2)fcC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CHa)6C(O)N(R42XR43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
[0027] In a further embodiment of the invention, X of a compound according to formula II is selected to be a O to give a compound of the formula III:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1^C(O)R11, -N(Rπ)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12)(R13), -OC(O)R11, -OC(O)N(R12XR13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-0-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R31, -(CH2)αC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)ΩC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and a is O to 6; or a pharmaceutically acceptable salt or hydrate thereof. [0028] In further preferred embodiment of the invention, R2 and R3 of a compound according to formula III are selected to be a -CH2-R and -CH2-R , respectively, to give a compound of the formula IV:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R l, -N(R12)(R13), -N(Rπ)C(O)Rπ, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
1XO 1X-X
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
[0029] In a preferred embodiment for compounds of the formula IY, R7 is selected to be an aryl or heteroaryl groups.
[0030] In another embodiment of the invention, R2 of a compound according to formula III is selected to be a benzyl group to give a compound of the formula V:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(R1^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)aC(O)R31, -(CH2)ΛC(O)N(R32)(R33), (CH2)«C(O)OR31, -(CH2)aC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R3 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -0-R81, -N(R82)(R83), -N(R81)C(O)RS1, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82')(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 maybe taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
[0031] In further preferred embodiment of the invention, R6 and R7 of a compound according to formula IV are selected to be phenyl groups, to give a compound of the formula VI:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12)(R13), -N(Rπ)C(O)Rn, -N(Ru)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-Ru, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and maybe further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82XR83), -N(R8 ^C(O)R81, -N(R81)SO2R81, -SRS1, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82|)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), ςycloalkyl, cycloalkenyl, aryl and heteroaryl; each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is 0 to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -0-R91, -N(R92)(R93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 2 and R93 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
[0032] Exemplary compounds of the formula VI include the following structures:
[0033] In a another embodiment of the invention, X of a compound according to formula II is selected to be a N-R4 to give a compound of the formula VII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1^C(O)R11, -N(R1OSO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12)(R13), -OC(O)R11, -OC(O)N(R12)(R13), CN5 CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-0-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)αC(O)N(R32)(R33), (CH2)^C(O)OR31, -(CH2)aC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is O to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)hC(O)R41, -(CH2)iC(O)N(R42)(R43), -(CH2)δC(O)OR41, and -(CH2)έC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is 0 to 6; or a pharmaceutically acceptable salt or hydrate thereof.
[0034] In a preferred embodiment for compounds of the formula VII, R3 is selected to be -CH=N-R34, to give a compound of the formula VII3
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12XR13), -N(R1 ^C(O)R11, -N(Rπ)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)^C(O)N(R42XR43), -(CH2)^C(O)OR41, and -(CH2)6C(O)N(R42)(R43), each R is- independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; & is O to 6; and R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or a pharmaceutically acceptable salt or hydrate thereof.
[0035] In a preferred embodiment for compounds of the formula VII and VIIa, R2 is selected to be an aryl or heteroaryl groups. I further preferred embodiments, R4 is H.
[0036] Exemplary compounds of the formula VIIa include the following structures:
[0037] In further preferred embodiment of the invention, R2 and R3 of a compound according to formula VII are selected to be a -CH2-R6 and -CH2-R7, respectively, to give a compound of the formula VIII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(R1^C(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)6C(O)N(R42)(R43), each R ' is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
[0038] In a preferred embodiment for compounds of the formula VIII, R7 is selected to be an aryl or heteroaryl groups.
[0039] In another embodiment of the invention, R2 of a compound according to formula VII is selected to be a benzyl group to give a compound of the formula IX: wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(R1^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12)(R13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, phosphate, phosphonate, halo, aryl and heteroaryl; additionally or alternatively two R substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R31, -(CH2)αC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)βC(O)N(R32)(R33), -(CH2)ΩN(R32)(R33), -CH-N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)ύC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)6C(O)N(R42)(R43), .♦ each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82O(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
[0040] In further preferred embodiment of the invention, R6 and R7 of a compound according to formula VIII are selected to be phenyl groups, to give a compound of the formula X:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12XR13), -N(R1^C(O)R11, -N(R11JSO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, phosphate, phosphonate, halo, aryl and heteroaryl; additionally or alternatively two R substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)6C(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -0-R81, -N(R82)(R83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82|)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is O to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -O-R91, -N(R92XR93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
[0041] In another embodiment of the invention, Y is selected to be a N-R5 to give a compound of the formula XI:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12)(R13), -N(R1^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)aC(O)R31, -(CH2)flC(O)N(R32)(R33), (CH2)aC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R3 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
X is selected from O and N-R4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)έC(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)δC(O)N(R42)(R43), each R4 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)iC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
[0042] In a further embodiment of the invention, X of a compound according to formula XI is selected to be a O to give a compound of the formula XII: wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12)(R13), -N(Rn)C(O)Rn, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)aC(O)R31, -(CH2)flC(O)N(R32)(R33), (CH2)flC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)flN(R32)(R33), -CH-N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R aanndd RR33 aarree independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)6C(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
[0043] In further preferred embodiment of the invention, R2 and R3 of a compound according to formula XII are selected to be a -CH2-R6 and -CH2-R7, respectively, to give a compound of the formula XIII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R , -N(R12)(R13), -N(R11)C(O)R11, -N(Rπ)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12)(R13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)6C(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
[0044] In a preferred embodiment for compounds of the formula XIII, R6 is selected to be an aryl or heteroaryl groups.
[0045] In another embodiment of the invention, R2 of a compound according to formula XII is selected to be a benzyl group to give a compound of the formula XIV:
(XIV) wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1 ^C(O)R11, -N(Rn)SO2Rn, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 maybe taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)aC(O)N(R32)(R33), (CH2)aC(O)OR31, -(CH2)flC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)ώC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -0-R81, -N(R82XR83), -N(R8 ^C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82O(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is 0 to 5; or a pharmaceutically acceptable salt or hydrate thereof.
[0046] In further preferred embodiment of the invention, R6 and R7 of a compound according to formula XIII are selected to be phenyl groups, to give a compound of the formula XV:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(Rn)C(O)Rn, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)iC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -0-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82t)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached1 form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is O to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -O-R91, -N(R92XR93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof. [0047] Exemplary compounds of the formula XV include the following structures:
[0048] In a another embodiment of the invention, X of a compound according to formula XI is selected to be a N-R4 to give a compound of the formula XVI:
wherein: each R is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R l, -N(R12)(R13), -N(R1^C(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R1 l is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)aC(O)N(R32)(R33), (CH2)aC(O)OR31, -(CH2)βC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)iC(O)R41, -(CH2)iC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)έC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R 2 and R 3 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)6C(O)R51, -(CH2)δC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
[0049] In further preferred embodiment of the invention, R2 and R3 of a compound according to formula XVI are selected to be a -CH2-R6 and -CH2-R7, respectively, to give a compound of the formula XVII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R , -N(R12XR13), -N(Rn)C(O)Rπ, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)έC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)ύC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 2 and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)έC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; & is O to 6;
R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
[0050] In a preferred embodiment for compounds of the formula XVII, R6 is selected to be an aryl or heteroaryl groups.
[0051] In another embodiment of the invention, R2 of a compound according to formula XVI is selected to be a benzyl group to give a compound of the formula XVIII:
(XVIII) wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12)(R13), -N(R1 ^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(0)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R31, -(CH2)βC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)aN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)6C(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 2 and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)feC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R ' aanndd RR53 aarree iinnddeeppeennddeennttllyy sseelleecctteedd frfroomm HH,, aallkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -0-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82O(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
[0052] In further preferred embodiment of the invention, R and R7 of a compound according to formula XVII are selected to be phenyl groups, to give a compound of the formula XIX:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(Rn)C(0)Rπ, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl,
10 1 "X alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)δC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)^C(O)N(R42XR43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)έC(O)R51, -(CH2)iC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -0-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82')(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is O to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R91, -0-R91, -N(R92XR93), -N(R91JC(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92)(R93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
[0053] The substances according to the invention may also be present as salts. In the context of the invention, preference is given to pharmaceutically acceptable salts. Pharmaceutically acceptable salts refers to an acid addition salt or a basic addition salt of a compound of the invention in which the resulting counter ion is understood in the art to be generally acceptable for pharmaceutical uses. Pharmaceutically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids. Preference is given to salts with inorganic acids, such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or to salts with organic carboxylic or sulfonic acids, such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid. Pharmaceutically acceptable salts can also be metal or ammonium salts of the compounds according to the invention. Particular preference is given to, for example, sodium, potassium, magnesium or calcium salts, and also to ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine. (see, Berge et al. J. Pharm. Sd. 1977, 66, 1-19.)
[0054] When one or more chiral centers are present in the compounds of the present invention, the individual isomers and mixtures thereof (e.g., racemates, etc.) are intended to be encompassed by the formulae depicted herein. In certain embodiments, compounds of the invention may exist in several tautomeric forms. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds. Compounds of the invention may exist in various hydrated forms.
[0055] It is understood that when n is a value greater than 1, each R1 group may be selected independently. Thus, when more than one R1 group is present, the R1 groups may be selected from any of the stated groups so as to be the same or different. This also holds true for any other group or substituent which may be selected independently from among various groups or values.
[0056] In another aspect of the invention, a synthetic process for the preparation of compounds of the invention is provided. The inventive process uses mild reaction conditions, which provides a high substituent tolerance. The product is obtained in high yield and high purity. A process of the present invention is illustrated by Scheme I: Scheme 1
A1 Bi
A2 B2
[0057] A1 and A2 may be treated with an alcohol (HO-R2) or amine (H2N-R2) in the presence of an appropriate base. LG represents a leaving group, such as halo, aryl sulfones (tosyl, etc.), triflate or other appropriate leaving group as would be recognized by the ordinarily skilled practitioner. The base may be selected from amine bases, hydroxide salts (non-limiting examples include sodium hydroxide and tetraalkylamonium hydroxides), carbonate salts, hydrides, alkoxide salts (non-limiting examples include sodium methoxide and potassium t- butoxide) and the like.
[0058] In other embodiments, compounds of the invention may be prepared according the reactions provided in Scheme 2:
Scheme 2
A3 B3
[0059] A3 and A4 may be treated with an activated benzyl group in the presence of an appropriate base. LG represents a leaving group, such as halo, aryl sulfones (tosyl, etc.), triflate or other appropriate leaving group as would be recognized by the ordinarily skilled practitioner. The base may be selected from amine bases, hydroxide salts (non-limiting examples include sodium hydroxide and tetraalkylamonium hydroxides), carbonate salts, hydrides, alkoxide salts (non-limiting examples include sodium methoxide and potassium t-butoxide) and the like.
[0060] In other embodiments, compounds of the invention may be prepared in the manner described in Scheme 3 : Scheme 3
[0061] A4 may be treated with an activated benzyl group in the presence of an appropriate base. LG represents a leaving group, such as halo, aryl sulfones (tosyl, etc.), triflate or other appropriate leaving group as would be recognized by the ordinarily skilled practitioner. The base may be selected from amine bases, hydroxide salts (non-limiting examples include sodium hydroxide and tetraalkylamonium hydroxides), carbonate salts, hydrides, alkoxide salts (non- limiting examples include sodium methoxide and potassium t-butoxide) and the like. [0062] It may be advantageous to employ a temporary protecting group in achieving the final product. The phrase "protecting group" as used herein means temporary modifications of a potentially reactive functional group which protect it from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991).
[0063] The compounds and processes disclosed herein are useful in the production of a library of 3,4-disubstituted coumarin and quinolone derivatives for biological screening. Derivatives of coumarin and quinolone posses a range of biological activities. Coumarin-based and quinolone-based compounds have shown efficacy, for example, as antivirals. Particularly, the compounds of the present invention may be used to prevent or treat infection with HCV.
[0064] The identification of inhibitors of HCV replication and/or proliferation has been facilitated by the development of a cell based system to study HCV replication and assay for HCV inhibitors. Inhibition of HCV replication may be performed using the HCV Replicon Assay developed in the laboratories of Bartenschlager (Lohman et al, Science 285, 110-113, 1999) and Rice (Blight et al, Science 290, 1972-1974, 2000). The assay is performed using the Huh-Luc- Neo cell line (Lohman et al, Science 285, 110-113, 1999). Huh-Luc- Neo cells are a human hepatoma cell line (Huh-7) stably expressing a bi-cistronic subgenomic replicon containing the HCV IRES in which the structural proteins of HCV had been deleted and replaced by a construct containing sequences coding for the firefly luciferase reporter gene, the neomycin selectable marker and the EMCV IRES to direct expression of a truncated HCV genome expressing the structural proteins NS3, NS4A, NS4B, NS5A, and NS5B. HCV targets through which inhibitors could act to inhibit replication include the NS3 protease, the helicase/ATPase, NS5A, the NS5B- RNA dependent RNA polymerase, and the HCV IRES.
[0065] Expression of HCV IRES driven luciferase reporter activity and HCV RNA is measured to obtain indirect and direct measures of replication of HCV RNA respectively. Inhibitors of HCV replication and/or proliferation are determined by initially identifying molecules that inhibit expression of the HCV IRES driven luciferase reporter in this HCV Replicon Luciferase Assay. Cell viability assays and control cell based luciferase assays are then run on hits identified in the HCV Replicon Luciferase Assay to eliminate cytoxic compounds and non-specific compounds which act by inhibiting the luciferase enzyme. Validated inhibitors of HCV replication and/or proliferation are identified by evaluating HCV Replicon Luciferase hits that are specific and non-cytoxic and demonstrating that these compounds inhibit expression of HCV RNA using a quantitative PCR based approach (Taqman) using primers and probes specific for HCV RNA (HCV Replicon RNA Assay).
[0066] The HCV Replicon Assay may be used to predict compound efficacy in treatment and/or prevention of HCV infection as well as inhibition of HCV replication and/or proliferation. The HCV Replicon encompasses a multiplicity of viral and host targets through which an inhibitor could work to inhibit HCV Replication. Viral targets expressed in the HCV Replicon include the HCV IRES (for translation), NS3 Protease, the HCV Helicase/ATPase, NS5A phosphorylation, and the NS5B polymerase. Without being limited to theory, it is believed that the compounds of the present invention inhibit HCV replication. The compounds of the invention may inhibit replication as by acting on the IRES, NS3 protease, NS5B polymerase, Helicase/ATPase, or NS5A phosphorylation.
[0067] Thus, in another embodiment, the present invention provides pharmaceutical compositions comprising an anti-HCV effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, in combination with a pharmaceutically acceptable carrier or auxiliary agent. As used herein, the terms "pharmaceutically acceptable salts" and "hydrates" refer to those salts and hydrated forms of the compound that would favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion. Other factors, more practical in nature, which those skilled in the art may take into account in the selection include the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug. [0068] The invention also provides a method of treating HCV infection in a mammal, preferable a human, by administering to the mammal an effective amount of a compound of the present invention, a pharmaceutically acceptable salt or hydrate thereof, or a composition as described above. The compounds of the invention may be administered alone or may be administered in combination with other approved therapeutics, such as: an interferon (pegylated or not), preferably α-interferon, ribavirin, or interferon and ribavirin, or one or more other anti-HCV agent, such as an HCV protease inhibitor, HCV polymerase inhibitor, HCV IRES inhibitor, HCV Helicase and/or ATPase inhibitor, NS5A phosphorylation inhibitor, HCV NS2 inhibitor, or other HCV life cycle inhibitor. Combination therapies with may include a compound of the invention with multiple different inhibitors of HCV life cycle (immunomodulatory agents, Toll Like Receptor modulators, antisense therapeutics etc.). The agents that comprise a combination therapy may be administered together or separately, e.g., prior to, concurrently with or following the administration of the compound of the invention or pharmaceutically acceptable salt thereof. These additional agents may be combined with the compounds of this invention to create a single pharmaceutical dosage form. Alternatively these additional agents may be separately administered to the patient as- part of a multiple dosage form, for example, using a kit. Such additional agents may be administered to the patient prior to, concurrently with, or following the administration of wherein a compound of formula (I), or a pharmaceutically acceptable salt thereof.
[0069] The compounds of the present invention may be employed in solid or liquid form including, for example, amorphous powder or crystalline form, in solution or in suspension. They may be administered in numerous different ways, such as orally, parenterally, topically, transdermally or by inhalation. Oral administration or administration by injection is preferred. The choice of carrier and the content of active compound in the carrier are generally determined in accordance with the solubility and chemical properties of the desired product, the particular mode of administration and well established pharmaceutical practice. The pharmaceutical composition of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, and intralesional injection or infusion techniques.
[0070] Examples of liquid carriers include syrups, peanut oil, olive oil, water, saline and the like. For parenteral administration, emulsions, suspensions or solutions of the compounds according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, maybe used. Injectable forms must be fluid to the extent they can be easily syringed, and proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin. The pharmaceutical composition maybe in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example Tween 80) and suspending agents.
[0071 ] The pharmaceutical composition of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. Compounds of the invention may be enclosed in hard or soft shell gelatin capsules, or compressed into tablets. Examples of oral liquid dosage forms include solutions, suspensions, syrups, emulsions, soft gelatin capsules and the like. Carriers for oral use (solid or liquid) may include time delay materials known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax. To prepare a capsule, it may be advantageous to use lactose and a liquid carrier, such as high molecular weight polyethylene glycols.
[0072] Compositions and dosage forms prepared in accordance with the present invention optionally may contain lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silica gels combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets, capsules and the like. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, and capsules may be coated with shellac, sugar or both. When aqueous suspensions are used they may contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyols such as polyethylene glycol, propylene glycol and glycerol, and mixtures thereof also may be used. In addition, the active compound may be incorporated into sustained-release preparations and formulations. If desired, certain sweetening and/or flavoring and/or coloring agents may be added. Other suitable vehicles or carriers for the above noted formulations and compositions can be found in standard pharmaceutical texts, e.g. in "Remington's Pharmaceutical Sciences", The Science and Practice of Pharmacy, 19.sup.th Ed. Mack Publishing Company, Easton, Pa., (1995).
[0073] When these compounds or their pharmaceutically acceptable salts are formulated together with a pharmaceutically acceptable carrier, the resulting composition may be administered in vivo to mammals, such as man, to treat or prevent HCV virus infection. Such treatment may also be achieved using a compound of this invention in combination with other anti- viral agents which include, but are not limited to a-interferon and ribavirin. The additional agents may be combined with compounds of this invention to create a single dosage form. Alternatively these additional agents may be separately administered to a mammal as part of a multiple dosage form.
EXAMPLES
General Methods
[0074] Reaction solvents were commercially purchased from Acros and Aldrich without further purification and reagents were used as received. Reactions for the synthesis of the starting material were monitored by thin-layer chromatography (TLC) on 0.25 mm precoated Merck Silica Gel 60 F254, visualizing with ultraviolet light or phosphomolybdic acid stain. Flash column chromatography was performed on Merck Silica Gel 60 (230-400 mesh) using reagent grade hexanes, dichloromethane, methanol and ethyl acetate. [0075] Reaction reagents were commercially purchased from Alrich and used as received. 1H and 13C NMR spectra were recorded on a Varian 500 MHz spectrometer and are referenced to residual solvent peaks or to an internal reference of tetramethylsilane in CDCI3. LC-MS were obtained on a Micromass ZQ mass spectrameter in ES+ mode with a Water 2790 HPLC system. HPLC condition: Cl 8 column (3.5 μm, 2.1 X 50 mm, W93491F 26) using a flow rate of 0.4 mL/min in a gradient of 15-100% CH3CN in H2O in 9 min with 1 min wash.
Example 1
[0076] To the mixture of 1 (60 mg, 0.37 mmol) and K2CO3 (100 mg, 0.73 mmol) in acetone (3 mL), 2 (103 mg, 0.56 mmol) was added slowly. Then the reaction was stirred at 65 0C overnight. After cooled down, and filtered, the solvent was removed, the given residue was purified using PTLC (eluent: EtOAc/Petroleum ether = 1 :3) to give 3 (13.9 mg, 10%) as solid.
LC-MS (6.77 min, ES+): calcd: 478.10; Found: 479.48. 1H NMR (CDCl3): 7.72-7.63 (m, 2H), 7.62-7.52 (m, 3H), 7.52-7.43 (m, 2H), 7.43-7.34 (m, 3H), 7.314 (t, J = 7.5 Hz, IH), 5.13 (s, 2H), 3.977 (s, 2H).
LC-MS (6.81 min, ES+): calcd: 478.10; Found: 479.41. 1H NMR (CDCl3): 7.656 (d, J = 8 Hz, IH), 7.627 (AABB, J = 80.5, 8.5 Hz, 4H), 7.57 (t, J = 7.5 Hz, IH), 7.455 (AABB, J = 52, 8 Hz, 4H), 7.403 (d, J = 8 Hz, IH), 7.309 (t, J = 7.5 Hz, IH), 5.138 (s, 2H), 3.978 (s, 2H).
LC-MS (6.65 min, ES+): calcd: 370.16; Found: 371.45. 1H NMR (CDCl3): 7.72 (d, J = 8.5 Hz, IH), 7.523 (t, J = 8.5 Hz, IH), 7.376 (d, J = 8 Hz, IH), 7.297 (t, J = 8 Hz, IH), 7.31 (AABB, J = 45.5, 9.5 Hz, 4H), 7.175 (AABB, J = 81.5, 8 Hz, 4H), 5.072 (s, 2H), 3.913 (s, 2H), 2.421 (s, 3H), 2.314 (s, 3H).
LC-MS (6.68 min, ES+): calcd: 400.17; Found: 401.47. 1H NMR (CDCl3): 7.589 (d, J = 8.5 Hz, IH), 7.325 (d, J = 7.5 Hz, IH), 7.31 (d, J = 8.5 Hz, IH), 7.224 (s, IH), 7.216 (d, J = 8.0 Hz, IH), 7.171-7.115 (m, 3H), 6.999 (d, J - 7.5 Hz, IH), 6.857-6.835 (m, 2H), 5.006 (s, 2H), 3.890 (s, 2H), 3.874 (s, 3H), 2.4 (s, 3H), 2.298 (s, 3H).
LC-MS (6.71 min, ES+): calcd: 440.06; Found: 441.38. 1H NMR (CDCl3): 7.542 (d, J = 9.5 Hz5 IH), 7.412 (s, IH), 7.371 (s, IH), 7.4 ~ 7.35 (m, IH)5 7.3-7.24 (m, 2H), 7.2-7.15 (m, 3H)5 6.9-6.85 (m, 2H)5 5.002 (s, 2H)5 3.879 (s, 3H)5 3.861 (s, 2H). -
LC-MS (6.64 min, ES+): calcd: 400.17; Found: 401.47. 1H NMR (CDCl3): 7.595 (d, J = 9.0 Hz5 IH), 7.4-7.25 (m, 3H)5 7.25-7.15 (m, 2H), 7.15^7.05 (m, 3H)5 6.95-6.85 (m, 2H)5 5.01 (s, 2H)5 3.886 (s, 3H), 3.872 (s, 2H), 2.33 (s, 3H), 2.207 (s, 3H).
LC-MS (6.33 min, ES+): calcd: 444.10; Found: 445.46. 1H NMR (CDCl3): 7.576 (d, J = 9 Hz, IH), 7.428 (q, J = 15.5, 8 Hz5 IH), 7.223 (q, J = 15, 8 Hz5 IH)5 6.937 (t, J = 7.5 Hz5 IH)5 6.9-6.82 (m, 3H)5 6.763 (tt, J = 8.5, 2H), 5.078 (s, 2H), 3.825 (s, 5H).
LC-MS (6.51 min, ES+): calcd: 444.10; Found: 445.41. 1H NMR (CDCl3): 7.516 (d, J = 9.5 Hz, IH), 7.3-7.16 (m, 2H), 7.15-6.94 (m, 4H), 6.9-6.83 (m, 2H), 5.009 (s, 2H), 3.884 (s, 3H), 3.808 (s, 2H).
LC-MS (6.78 min, ES+): calcd: 508.11; Found: 509.46. 1H NMR (CDCl3): 7.7-7.63 (m, 2H), 7.6-7.5 (m, 4H), 7.5-7.42 (2H), 7.4-7.33 (m, IH), 6.85-6.82 (m, 2H), 5.097 (s, 2H), 3.939 (s, 2H), 3.885 (s, 3H).
LC-MS (6.84 min, ES+): calcd: 508.11; Found: 509.45. 1H NMR (CDCl3): 7.614 (AABB, J = 85.5, 8.5 Hz, 4H), 7.53 (d, J = 8 Hz, IH), 7.446 (AABB, J = 55, 8 Hz, 4H), 6.875 (s, IH), 6.866 (d, J = 8 Hz, IH), 5.106 (s, 2H), 3.94 (s, 2H), 3.884 (s, 3H).
VQJ 1763 LC-MS (6.68 min, ES+): calcd: 400.17; Found: 401.47. 1H NMR (CDCl3): 7.576 (d, J = 8 Hz, IH), 7.226 (AABB, J = 8, 4 Hz, 4H), 7.19 (AABB, J = 121, 8 Hz, 4H), 6.845 (s, IH), 6.837 (d, J = 8 Hz, IH), 5.028 (s, 2H), 3.869 (s, 3H), 3.859 (s, 2H), 2.40 (s, 3H), 2.294 (s, 3H).
LC-MS (6.64 min, ES+): calcd: 442.12; Found: 443.40. 1H NMR (CDCl3): 7.438 (q, J = 14.5, 8 Hz, IH), 7.41 (s, IH), 7.21 (q, J = 15.5, 8.5 Hz, IH), 7.16 (s, IH), 6.942 (t, J = 8 Hz, IH), 6.881 (t, J = 8 Hz, IH), 6.81-6.7 (m, 2H), 5.081 (s, 2H), 3.882 (s, 2H), 2.36 (s, 3H), 2.306 (s, 3H).
Example 2
[0077] POCl3 was added slowly to the solution of 1 in DMF at -5— 10 °C (ice bath). Then the mixture stirred for 1 hr at r.t. and for another 2 hrs at 60 0C. After cooling down, the mixture was poured to the crushed ice in the flask and stored at 0 °C overnight. Then filtered, and washed down with 5% Na2CO3 solution and water followed by drying in vacuum to give 2. [0078] 4-Methyl aniline was dissolved in MeOH and added slowly to the mixture of 2 and Et3N in MeOH and in a couple minutes the precipitation of 3 formed. After filtration, washing down with MeOH, and drying in vacuum amine was added to the solution 3 in THF and the mixture stirred overnight followed adding NaBH4 to acquired 4. And VQ_36344 is the result of the direct reduction of 3.
1H NMR (CDCl3): 7.581 (br, IH), 7.44 (t, J - 7.5 Hz, IH), 7.351 (d, J = 7.5 Hz, IH), 7.301 (d, J = 7.5 Hz, IH), 7.023 (t, J = 7.5 Hz, IH), 7.017 (AABB, J = 93, 7.5 Hz, 4H), 4.733 (s, 2H), 4.2 (br, IH), 3.818 (s, 3H), 3.614 (d, J = 7.5 Hz, IH), 3.60 (d, J = 6.5 Hz, IH), 2.339 (s, 3H).
1H NMR (CDCl3): 8.471 (s, IH), 8.394 (d, J = 4.5 Hz, IH), 7.579 (br, IH), 7.437 (t, J = 7.5 Hz, IH), 7.35 (d, J = 8.5 Hz, IH), 7.30 (d, J = 8.5 Hz, IH), 7.022 (t, J = 7.0 Hz, IH), 7.014 (AABB, J = 93.5, 8.0 Hz, 4H), 6.725 (t, J = 6.0 Hz, IH), 4.737 (s, 2H), 2.338 (s, 3H).
1H NMR (CDCl3): 7.456 (t, J = 8.0 Hz, IH)3 7.411 (d, J = 8.0 Hz, IH), 7.355 (d, J = 8.0 Hz, IH), 7.124 (t, J = 8.0 Hz, IH), 6.975 (AABB, J = 132.5, 7.5 Hz, 4H), 6.064 (br, IH), 2.333 (s, 3H), 2.031 (s, 3H).
Example 3
[0079] To the mixture of 1 (50 mg, 0.285 mmol) and K2CO3 (197 mg, 1.43 mmol) in acetone (3 mL), 2 (158 mg, 0.854 mmol) was added slowly. Then the reaction was stirred at 65 0C overnight. After cooled down, and filtered, the solvent was removed, the given residue was purified using PTLC (eluent: EtO Ac/Petroleum ether = 1 :3) to give 3 (81.3 mg, 74.3%) and 4 (23.2 mg, 21.2%) as solids.
LC-MS (6.42 min, ES+): calcd: 383.48; Found: 384.39. 1H NMR (CDCl3): 7.85 (dd, J = 8.0, 2.0 Hz, IH), 7.326 (dt, J = 9.0, 2.0 Hz, IH), 6.961 (t, J = 7.5 Hz, IH), 6.88 (AABB, J = 46, 8.5 Hz, 8H), 6.66 (d, J = 8.5 Hz, IH), 3.42 (s, 2H), 3.188 (s, 2H), 2.146 (s, 6H). Example 4
To the mixture of 1 (50 mg, 0.31 mmol) and K2CO3 (429 mg, 3.1 mmol) in acetone (3 mL), 2 (345 mg, 1.86 mmol) was added slowly. Then the reaction was stirred at 65 0C overnight. After cooled down, and filtered, the solvent was removed, the given residue was purified using PTLC (eluent: EtO Ac/Petroleum ether = 1:3) to give 3 (61.3 mg, 25.6%), 4 (43.9 mg, 38.3%) and 5 (12.6 mg, 8.6%) as solids.
LC-MS (6.90 min, ES+): calcd: 473.60; Found: 474.48. 1HNMR (CDCl3): 7.92 (d, J = 8.5 Hz, IH), 7.165 (t, J = 8.5 Hz, IH), 6.947 (AABB, J = 33.5, 8.5 Hz, 4H), 6.931 (AABB, J - 49, 8.5 Hz, 4H), 6.922 (t, J = 8.5 Hz, IH), 6.71 (AABB, J = 189, 8.5 Hz, 4H), 6.52 (d, J = 8.5 Hz, IH), 5.0 Qx, 2H), 3.583 (s, IH), 3.557 (s, IH), 3.452 (s, IH), 3.427 (s, IH), 2.273 (s, 3H), 2.21 (s, 6H).
Example 5
HCVReplicon Luciferase Assay
[0080] Day 0, Cell Seeding and Compound Treatment: Huh-Luc-Neo Cells are seeded at 25,000/well in an opaque-walled 96 plate with Growth Medium (DMEM phenol red free + PS + 2mM glutamine; 100 μl/well). The compounds to be tested are added to the experimental wells (10 μl/well at 1OX assay concentration) and the cells are then incubated (5% CO2, 370C) for 48h.
[0081] Day 2, Reagent Preparation and Luciferase Assay: The Bright-Glo Luciferase Assay Buffer (Promega) is thawed and equilibrated to room temperature prior to use. The lyophilized Bright-Glo Luciferase Assay Substrate is equilibrated to room temperature prior to use. 10 ml of Bright-Glo Luciferase Assay Buffer is transferred to 1 vial of Bright-Glo Luciferase Assay Substrate bottle and mixed by gently with a Vortex. 100 ul of Bright-Glo Luciferase Assay reagent (Bright-Glo Luciferase Assay Buffer + Bright-Glo Luciferase Assay Substrate Mixture) is added to each well. The well contents are mixed for 5 min. on an orbital shaker at room temperature to induce cell lysis and the luminescence is then measured using a luminometer. The data is analyzed and IC50s are determined using GraphPad Prism 4 software. Hits validated in the Replicon Luciferase assay have IC50s < 8.0 μM and show < 30% inhibition of Cell Viability at a compound concentration of 100 μM (Cell Titer Glow Assay, cell viability assay conditions identical to HCV Replicon Luciferase Assay conditions).
Example 6
HCV Replicon RNA Assay
[0082] Day 0, Cell Seeding and Compound Treatment: Huh-Luc-Neo Cells are seeded at 25,000/well in an opaque-walled 96 plate with Growth Medium (DMEM phenol red free + PS + 2mM glutamine; 100 μl/well). The compounds to be tested are added to the experimental wells (10 μl/well at 1OX assay concentration) and the cells are then incubated (5% CO2, 370C).
[0083] Day 1 , Media Change and Compound Treatment: 24 hours after the initial compound treatment the cell culture media is aspirated from the wells and fresh Growth Medium is added (DMEM phenol red free + PS + 2mM glutamine; 100 μl/well). The compounds to be tested are then added to the appropriate experimental wells (10 μl/well at 1OX assay concentration) and the cells are then incubated (5% CO2, 370C) for an additional 24 hrs.
[0084] Day 2. RNA Isolation and cDNA Synthesis: The cells are washed with IX Phosphate Buffered Saline (PBS) once. Cells are then lysed and RNA is isolated in 96 well format using a vacuum manifold and the RNAeasy 96 kit (Qiagen) according to the manufacturer's suggested protocol. cDNA is then synthesized from RNA isolated from each well using the Taqman Reverse Transcription Reagents kit (Applied Biosystems) according to manufacturer's suggested protocol.
[0085] Day 3, Quantitative PCR Based Measurement of HCV RNA fTagman Assay): Quantitative PCR analysis to measure HCV RNA expression from cDNA synthesized on Day 2 is performed using the ABI 9700 HT Sequence Detection System (Applied Biosystems) as previously described (Lohman et al, Science 285, 110-113, 1999). The data is analyzed and IC50s are determined using GraphPad Prism 4 software. Hits validated in the Replicon RNA Assay have IC50s < 8.0 μM and show < 30% inhibition of Cell Viability at a compound concentration of 50 μM (Cell Titer Glow Assay, cell viability assay conditions identical to HCV Replicon RNA Assay conditions).
Example 7
CellTiter-Glo Cell Viability Assay (Promega)
[0086] Day 0, Cell Seeding and Compound Treatment: Huh-Luc-Neo Cells are seeded at 25,000/well in an opaque-walled 96 plate with Growth Medium (DMEM phenol red free + PS + 2mM glutamine; lOOul/well). The compounds to be tested for inhibition of cell viability are added to the experimental wells (10 μl/well at 1OX assay concentration) and the cells are then incubated (5% CO2, 370C) for 48h.
[0087] Day 2. Reagent Preparation and Assay: The CellTiter-Glo Buffer is thawed and equilibrated to room temperature prior to use. The lyophilized CellTiter-Glo Substrate is equilibrated to room temperature prior to use. 10 ml of CellTiter-Glo Buffer is transferred to 1 vial of CellTiter-Glo Substrate and mixed by gently with a Vortex. 100 μl of CellTiter-Glo Assay reagent (CellTiter-Glo Buffer + CellTiter-Glo Substrate Mixture) is added to each well. The well contents are mixed for 5 min. on an orbital shaker at room temperature to induce cell lysis and the luminescence is then measured using a luminometer. Table 1
comp. # Structure Luciferase Toxicity TaqMan Toxicity
% Inhibition % Inhibition
IC50 at lOOuM IC50 at 5OuM
(1 dose) (2 doses)
VQ_36467 51.13 22.8 0.46 13.9
VQ_36468 43.30 40.7 0.71 16.3
VQ_36469 53.64 14.7 4.16 3.3
VQ_36470 59.94 12.5 4.08 -2.7
VQ_36471 0.04 9.8 1.78 15.2
VQ 36472 0.03 5.9 0.85 6.5
VQ_36473 0.02 4.3 1.71 10.7
VQ 36594 0.74 9.1 >30 13.7 comp. # Structure Luciferase Toxicity TaqMan Toxicity
% Inhibition % Inhibition
IC50 at lOOuM IC50 at 5OuM
(1 dose) (2 doses)
VQ_32833 2.89 34.6 0.58 20.7
VQ_33645 2.33 21.5 >30 17.2
VQ_34453 8.5 24.6 1.97 12.2
VQ_35027 2.1 4.6 Inactive 12.5
VQ_35018 1.0 10.0 Inactive 12.3

Claims

What is claimed is:
1. A method of treating HCV infection in a human comprising administering a therapeutically effective amount of a compound of Formula I:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R , -N(R12XR13), -N(R1^C(O)R1 \ -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11,
-C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R1 ' is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)βC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
X is selected from O and N-R4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)iC(O)N(R42)(R43), -(CH2)6C(O)OR41, and -(CH2)δC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; Y is selected from O and N-R5;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)δC(O)R51, -(CH2)6C(O)N(R52)(R53), and -(CH2)δC(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is 0 to 6; or a pharmaceutically acceptable salt or hydrate thereof.
2. The method of claim 1, comprising administering a compound of the formula II:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12XR13), -N(R1^C(O)R11, -N(Rn)SO2Rn, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, phosphate, phosphonate, halo, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 2 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)ΩC(O)N(R32)(R33), (CH2)ΩC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)βN(R32)(R33), -CH-N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; a is 0 to 6;
X is selected from O and N-R4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)^C(O)N(R42XR43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 2 and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
3. The method of claim 2, comprising administering a compound of the formula III:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(Rn)C(O)Ru, -N(R1 ^SO2R1 \ -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)aC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R3 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and a is 0 to 6; or a pharmaceutically acceptable salt or hydrate thereof.
4. The method of claim 3, comprising administering a compound of the formula IV: wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12XR13), -N(R11JC(O)R11, -N(R11JSO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R ; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
5. The method of claim 4, comprising administering a compound of the formula IV, wherein R7 is selected to be an aryl or heteroaryl group.
6. The method of claim 3, comprising administering a compound of the formula V:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R l, -N(R12XR13), -N(R11XXO)R11, -N(Rπ)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R , 3'11, -(CH2)βC(O)N(R 3J20w(Rr,3 J30N> (CH2)αC(O)OR > 31 -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -O-R81, -N(R82)(R83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82|)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
7. The method of claim 4, comprising administering a compound of the formula VI:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12)(R13), -N(R11XJ(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12)(R13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -O-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82')(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is O to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -O-R91, -N(R92XR93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 maybe taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is 0 to 5; or a pharmaceutically acceptable salt or hydrate thereof.
8. The method of claim 2, comprising administering a compound of the formula VII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1^C(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)βC(O)R31, -(CH2)flC(O)N(R32)(R33), (CH2)flC(O)OR31, -(CH2)βC(O)N(R32)(R33), -(CH2)aN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)^C(O)N(R42XR43), -(CH2^C(O)OR41, and -(CH2),C(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R 2 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
9. The method of claim 8, comprising administering a compound of the formula VII3:
(Vila) wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(R1^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-Ru, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)6C(O)R41, -(CH2)δC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)fcC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; and R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or a pharmaceutically acceptable salt or hydrate thereof.
10. The method of claim 9, comprising administering a compound of the formula VIIa wherein R is selected from the group consisting of aryl and heteroaryl.
11. The method of claim 10, comprising administering a compound of the formula VIIa wherein R2 is selected from the group consisting of aryl and heteroaryl, and R4 is H.
12. The method of claim 8, comprising administering a compound of the formula VIII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1 ^C(O)R11, -N(Rn)SO2Rn, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)έC(O)N(R42)(R43), -(CH2)z,C(O)OR41, and -(CH2)έC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; & is 0 to 6;
R is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R3 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
1XO "X1X or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
13. The method of claim 12, comprising administering a compound of the formula VIII wherein R7 is selected from the group consisting of aryl and heteroaryl groups.
14. The method of claim 8, comprising administering a compound of the formula IX:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12)(R13), -N(R1 ^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)αC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 2 and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is O to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)έC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CHz)6C(O)N(R42XR43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -0-R81, -N(R82XR83), -N(R81JC(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82|)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
15. The method of claim 12, comprising administering a compound of the formula X:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(Rπ)C(O)Ru, -N(R11JSO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13)5 CN5 CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-0-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)^C(O)N(R42XR43), -(CH2)6C(O)OR4i, and -(CH2)*C(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82XR83), -N(R81)C(O)R81, -N(RS1)SO2RSI, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82')(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, SO $.1 alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is 0 to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -0-R91, -N(R92XR93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 maybe taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
16. The method of claim 1, comprising administering a compound of the formula XI:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(R11XXO)R11, -N(Rn)S02Ru, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R ; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R31, -(CH2)αC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
X is selected from O and N-R4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2^C(O)R41, -(CH2)έC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)έC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)6C(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
17. The method of claim 16, comprising administering a compound of the formula XII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)flC(O)R31, -(CH2)βC(O)N(R32)(R33), (CH2)flC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)έC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
8. The method of claim 17, comprising administering a compound of the formula XIII:
^herein: ach R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(R1 ^C(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, is O to 4;
5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)δC(O)R51, -(CH2)6C(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6;
R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
19. The method of claim 18, comprising administering a compound of the formula XIII wherein R6 is selected from the group consisting of aryl and heteroaryl groups.
20. The method of claim 17, comprising administering a compound of the formula XIV:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(R11XXO)R11, -N(Rn)S02Rn, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)flC(O)R31, -(CH2)ΩC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)flN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)έC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R81, -0-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82')(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 maybe taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
21. The method of claim 18, comprising administering a compound of the formula XV:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(Rn)C(0)Rn, -N(Rπ)S02Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)iC(O)N(R52)(R53), and -(CH2)AO)OR51; each R5 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82XR83), -N(R8I)C(O)R81, -N(Rδl)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82|)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is O to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -0-R91, -N(R92XR93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
22. The method of claim 16, comprising administering a compound of the formula XVI:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R l, -N(R12XR13), -N(R11XXO)R11, -N(Rπ)S02Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF35 NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)aC(O)N(R32)(R33), (CH2)aC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)αN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl α is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)δC(O)R41, -(CH2)έC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)όC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)6C(O)R51, -(CH2)έC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is 0 to 6; or a pharmaceutically acceptable salt or hydrate thereof. 1
23. The method of claim 22, comprising administering a compound of the formula XVII:
(XVII) wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(R1^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)iC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)έC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; . b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)fcC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
24. The method of claim 23, comprising administering a compound of the formula XVII wherein R6 is selected from the group consisting of aryl or heteroaryl groups.
25. The method of claim 22, comprising administering a compound of the formula XVIII:
(XVIII) wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(Rπ)C(O)Rπ, -N(R11JSQ2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R31, -(CH2)flC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)aN(R32)(R33), -CH-N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CHa)6C(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2),C(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl. aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)6C(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82)(R83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82l)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is 0 to 5; or a pharmaceutically acceptable salt or hydrate thereof.
26. The method of claim 17, comprising administering a compound of the formula XIX:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12XR13), -N(R11XJ(O)R11, -N(Rn)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)^C(O)N(R42XR43), each R ' is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 2 and R 3 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)^C(O)N(R52XR53), and -(CH2)^C(O)OR51; each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -O-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82O(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is 0 to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -0-R91, -N(R92)(R93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
27. The method of claim 7, comprising administering a compound of the formula
28. The method of claim 7, comprising administering a compound of the formula
29. The method of claim 7, comprising administering a compound of the formula
30. The method of claim7 , comprising administering a compound of the formula
31. The method of claim 7, comprising administering a compound of the formula
32. The method of claim 7, comprising administering a compound of the formula
33. The method of claim 7, comprising administering a compound of the formula
34. The method of claim 7, comprising administering a compound of the formula
35. The method of claim 7, comprising administering a compound of the formula
36. The method of claim 7, comprising administering a compound of the formula
37. The method of claim 7, comprising administering a compound of the formula
38. The method of claim 7, comprising administering a compound of the formula
39. The method of claim 6, comprising administering a compound of the formula
40. The method of claim 8, comprising administering a compound of the formula
41. The method of claim 8, comprising administering a compound of the formula
42. The method of claim 9, comprising administering a compound of the formula
43. The method of claim 9, comprising administering a compound of the formula
44. The method of claim 9, comprising administering a compound of the formula
45. The method of claim 9, comprising administering a compound of ..the formula
46. The method of claim 9, comprising administering a compound of the formula
47. The method of claim 9, comprising administering a compound of the formula
48. The method of claim 9, comprising administering a compound of the formula
49. The method of claim 21, comprising administering a compound of the formula
50. The method of claim 21, comprising administering a compound of the formula
51. The method of claim 21, comprising administering a compound of the formula
52. The method of claim 21, comprising administering a compound of the formula
53. The method of claim 21, comprising administering a compound of the formula
54. The method of claim 21, comprising administering a compound of the formula
55. The method of claim 1, comprising administering a therapeutically effective amount of a combination of the compound having the formula I, or a therapeutically acceptable salt or hydrate thereof, and at least one additional agent selected from an interferon, ribavirin, an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV IRES inhibitor, an HCV Helicase, an HCV ATPase inhibitor, an NS5A phosphorylation inhibitor, and an HCV NS2 inhibitor.
56. The method of claim 55, wherein the at least one additional agent is an interferon.
57. The method of claim 56, wherein the at least one additional agent is α-interferon.
58. The method of claim 55, wherein the at least one additional agent is an interferon and ribavirin.
59. A compound having the formula II:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(R1 ^C(O)R11, -N(Rπ)S02Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, phosphate, phosphonate, halo, aryl and heteroaryl; additionally or alternatively two R substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)flC(O)N(R32)(R33), (CH2)QC(O)OR31, -(CH2)aC(O)N(R32)(R33), -(CH2)aN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached 1 form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; a is 0 to 6;
X is selected from O and N-R4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, ■ heteroaryl, -(CH2)^C(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)iC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is O to 6; or a pharmaceutically acceptable salt or hydrate thereof.
50. The compound of claim 59, having the formula III:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1^C(O)R11, -N(Ru)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R! substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)aC(O)R31, -(CH2)flC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)aN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom;
R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and a is 0 to 6; or a pharmaceutically acceptable salt or hydrate thereof.
61. The compound of claim 60, having the formula IV:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1^C(O)R1 ', -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, ■i is O to 4;
R6 is selected from the group consisting of aryl and heteroaryl; R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32)(R33), and -N(R32)(R33),
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
62. The compound of claim 61, wherein R7 is selected to be an aryl or heteroaryl group.
63. The compound of claim 60, having the formula V:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(R11XXO)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13); CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)ΛC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)ΛC(O)N(R32)(R33), -(CH2)ΩN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R3 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -O-R81, -N(R82XR83), -N(R8 ^C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82|)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
64. The compound of claim 61, having the formula VI: wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(Rn)C(O)Rn, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12)(R13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R1 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82XR83), -N(R81XJ(O)R81, -N(R8 ^SQ2R81, -SR81, -C(O)N(RS2)(R83), -OC(O)R81, -OC(O)N(R82O(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is 0 to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -0-R91, -N(R92)(R93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R ] is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 maybe taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
65. The compound of claim 59, having the formula VII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(R1^C(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(RI2)(R13), CN, CF35 NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)flC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)flN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)6C(O)N(R42)(R43), -(CH2)δC(O)OR41, and -(CH2)*C(O)N(R42)(R43), each R * is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is 0 to 6; or a pharmaceutically acceptable salt or hydrate thereof.
66. The compound of claim 65, having the formula VIIa:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1 ^C(O)R11, -N(Rπ)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2^C(O)R41, -(CH2)δC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)^C(O)N(R42XR43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; and R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or a pharmaceutically acceptable salt or hydrate thereof.
67. The compound of claim 66, wherein R2 is selected from the group consisting of aryl and heteroaryl.
68. The compound of claim 67, wherein R is H.
69. The compound of claim 65, having the formula VIII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(Rπ)C(O)Rn, -N(Rn)SO2Rn, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)z,C(O)R41, -(CH2)/,C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)έC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R 2 and R 3 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R3 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
70. The compound of claim 69, wherein, R is selected from the group consisting of aryl and heteroaryl groups.
71. The compound of claim 65, having the formula IX:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-Rn, -N(R12)(R13), -N(Rn)C(O)Rn, -N(R1^SO2R1 \ -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, ~OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)aC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)flN(R32)(R33), -CH=N-R34, R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)όC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)^C(O)N(R42XR43), each R 1 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R8l)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82t)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
72. The compound of claim 69, having the formula X:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(Rn)C(O)Rn s -N(Rn)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)*C(O)N(R42)(R43), -(CH2)^C(O)OR41, and
-(CH2)6C(O)N(R42)(R43), eac ;hh RR4411 iiss iinnddeeppeennddeently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82)(R83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82O(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is O to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R , C(O)R91, -O-R91, -N(R92XR93), -N(R91XXO)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
73. A compound having the formula XIII: wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12)(R13), -N(R11JC(O)R11, -N(Rπ)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12)(R13), -OC(O)R11, -OC(O)N(R12XR13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^1C(O)R51, -(CH2)6C(O)N(R52)(R53), and -(CH2)6C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R5 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R 2 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
74. The compound of claim 73, wherein R6 is selected from the group consisting of aryl and heteroaryl groups.
75. The compound of claim 73, having the formula XV:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -0-R11, -N(R12XR13), -N(R1 ^C(O)R11, -N(Rπ)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)6C(O)R51, -(CH2)&C(O)N(R52)(R53), and -(CH2)iC(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82)(R83), -N(R8 ^C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82O(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is O to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -0-R91, -N(R92XR93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92)(R93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 maybe taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
76. A compound having the formula XIV:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(Rn)C(0)Ru, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CHs)0C(O)R31, -(CH2)flC(O)N(R32)(R33), (CH2)aC(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)aN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)όC(O)N(R52)(R53), and -(CH2)^C(O)OR51; eac ;hh RR iiss iinnddeeppeennddeennttllyy sseelleecctteedd frfroomm HH,, aallkkyyll,, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R ' aanndd RR aarree iinnddeeppeennddeennttllyy sseelleecctteedd frfroomm HH,, aallkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; oorr RR aanndd RR mmaayy bbee ttaakkeenn ttooggeetthheerr wwiitthh tthhee nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82XR83), -N(R81)C(O)R81, -N(R8l)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82|)(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is 0 to 5; or a pharmaceutically acceptable salt or hydrate thereof.
77. A compound having the formula XVI:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(Rπ)C(O)Ru, -N(Rπ)SO2Rπ, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4; R2 is selected from the group consisting of aralkyl, aryl, heteroaryl, cycloalkyl and cycloalkenyl; R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)αC(O)R31, -(CH2)αC(O)N(R32)(R33), (CH2)^C(O)OR31, -(CH2)αC(O)N(R32)(R33), -(CH2)aN(R32)(R33), -CH=N-R34,
R31 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is O to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)6C(O)R41, -(CH2)iC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)iC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)έC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and b is 0 to 6; or a pharmaceutically acceptable salt or hydrate thereof.
78. The compound of claim 77, having the formula XVII:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12XR13), -N(R1^C(O)R11, -N(R1 ^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R ; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)δC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)6C(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is 0 to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)6C(O)R51, -(CH2)*C(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R52 and R53 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R6 is selected from the group consisting of aryl and heteroaryl;
R7 is selected from the group consisting of aryl, heteroaryl, -C(O)R31, -C(O)N(R32)(R33), -C(O)OR31, -C(O)N(R32XR33), and -N(R32)(R33),
R3 selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; and
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; or a pharmaceutically acceptable salt or hydrate thereof.
79. The compound of claim 78, wherein R6 is selected from the group consisting of aryl or heteroaryl groups.
80. The compound of claim 77, having the formula XVIII:
(XVIII) wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -OR11, -N(R12XR13), -N(Rπ)C(O)Rπ, -N(R1 ^SO2R1 \ -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12)(R13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is O to 4;
R3 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R31, -(CH2)βC(O)N(R32)(R33), (CH2)αC(O)OR31, -(CH2)aC(O)N(R32)(R33), -(CH2)aN(R32)(R33), -CH-N-R34,
R selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; R32 and R33 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R32 and R33 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; R34 is selected from alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl a is 0 to 6;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)ύC(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)^C(O)N(R42XR43), each R x is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R 2 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; & is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)έC(O)N(R52)(R53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R52 and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -O-R81, -N(R82)(R83), -N(R81)C(O)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82')(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and m is 0 to 5; or a pharmaceutically acceptable salt or hydrate thereof.
81. The compound of claim 78, having the formula XIX:
wherein: each R1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, -O-R11, -N(R12)(R13), -N(R1^C(O)R11, -N(R1^SO2R11, -SR11, -C(O)R11, -C(O)OR11, -C(O)N(R12XR13), -OC(O)R11, -OC(O)N(R12)(R13), CN, CF3, NO2, SO2, -SOR11, -SO3R11, -SO2N(R12XR13), -alkyl-O-R11, cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and heteroaryl; additionally or alternatively two R1 substituents on adjacent ring atoms my be combined to form a fused 5 or 6- membered ring, wherein the fused 5- or 6- membered ring may contain from O to 3 ring heteroatoms and may be further substituted with on or more substituents selected from R1; each R11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and heteroaryl; each R12 and R13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R12 and R13 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom, n is 0 to 4;
R4 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R41, -(CH2)»C(O)N(R42)(R43), -(CH2)^C(O)OR41, and -(CH2)ύC(O)N(R42)(R43), each R41 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R42 and R43 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R42 and R43 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6;
R5 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, -(CH2)^C(O)R51, -(CH2)^C(O)N(R52XR53), and -(CH2)^C(O)OR51; each R51 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl;
R and R are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R and R53 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; b is O to 6; each R8 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R81, C(O)R81, -0-R81, -N(R82XR83), -N(R81XXO)R81, -N(R81)SO2R81, -SR81, -C(O)N(R82)(R83), -OC(O)R81, -OC(O)N(R82O(R83), SO2, -SOR81, -SO3R81, -SO2N(R82)(R83), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R81 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R82 and R83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R82 and R83 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; m is 0 to 5; each R9 is independently selected from the group consisting of halo, alkyl, CN, NO2, CO2R91, C(O)R91, -0-R91, -N(R92)(R93), -N(R91)C(O)R91, -N(R91)SO2R91, -SR91, -C(O)N(R92)(R93), -OC(O)R91, -OC(O)N(R92XR93), SO2, -SOR91, -SO3R91, -SO2N(R92)(R93), cycloalkyl, cycloalkenyl, aryl and heteroaryl; each R91 is independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; each R92 and R93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and heteroaryl; or R92 and R93 may be taken together with the nitrogen to which they are attached form a 5- to 7- membered ring which may optionally contain a further heteroatom; and p is O to 5; or a pharmaceutically acceptable salt or hydrate thereof.
82. The compound of claim 64, having the formula
83. The compound of claim 64, having the formula
84. The compound of claim 64, having the formula
85. The compound of claim 64, having the formula
86. The compound of claim 64, having the formula
87. The compound of claim 64, having the formula
88. The compound of claim 64, having the formula
89. The compound of claim 64, having the formula
90. The compound of claim 64, having the formula
91. The compound of claim 64, having the formula
92. The compound of claim 64, having the formula
93. The compound of claim 64, having the formula
94. The compound of claim 63, having the formula
95. The compound of claim 65, having the formula
96. The compound of claim 65, having the formula
97. The compound of claim 66, having the formula
98. The compound of claim 66, having the formula
99. The compound of claim 66, having the formula
100. The compound of claim 66, having the formula
101. The compound of claim 66, having the formula
102. The compound of claim 66, having the formula
103. The compound of claim 66, having the formula
104. The compound of claim 75, having the formula
105. The compound of claim 75, having the formula
106. The compound of claim 75, having the formula
107. The compound of claim 75, having the formula
108. The compound of claim 75, having the formula
109. The compound of claim 75, having the formula
EP06759899A 2006-05-15 2006-05-15 3,4-disubstituted coumarin and quinolone compounds Withdrawn EP2028938A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/018857 WO2007133211A1 (en) 2006-05-15 2006-05-15 3,4-disubstituted coumarin and quinolone compounds

Publications (2)

Publication Number Publication Date
EP2028938A1 true EP2028938A1 (en) 2009-03-04
EP2028938A4 EP2028938A4 (en) 2010-07-07

Family

ID=38694184

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06759899A Withdrawn EP2028938A4 (en) 2006-05-15 2006-05-15 3,4-disubstituted coumarin and quinolone compounds

Country Status (5)

Country Link
EP (1) EP2028938A4 (en)
JP (1) JP2009537518A (en)
AU (1) AU2006343604A1 (en)
CA (1) CA2694955A1 (en)
WO (1) WO2007133211A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312406A1 (en) * 2008-06-12 2009-12-17 Hsing-Pang Hsieh Coumarin compounds and their use for treating viral infection
JP2016510000A (en) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068450A1 (en) * 2004-01-06 2005-07-28 Vivoquest, Inc. 4-thio coumarins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533882B1 (en) * 1991-04-03 2001-02-07 Korea Research Institute Of Chemical Technology 2-quinolinone derivatives, methods for preparing the same and fungicides and insecticides including them
IL123701A (en) * 1995-10-13 2002-03-10 Agrevo Uk Ltd Heterocyclic fungicides and some new compounds
FR2749585B1 (en) * 1996-06-11 1998-08-14 Hoechst Marion Roussel Inc NOVEL AROMATIC DERIVATIVES SUBSTITUTED BY RIBOSIS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068450A1 (en) * 2004-01-06 2005-07-28 Vivoquest, Inc. 4-thio coumarins

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ANSCHÜTZ R: "Ueber die Benzotetronsäuregruppe" JUSTUS LIEBIGS ANALEN DER CHEMIE, vol. 367, 1 January 1909 (1909-01-01), pages 219-270, XP002576917 *
BANDYOPADHYAY C ET AL: "Synthesis of coumarin derivatives from 4-oxo-4H-1-benzopyran-3-caroboxaldehyde via 3-(arylaminomethylene)chromane-2,4-dione" TETRAHEDRON, vol. 56, 1 January 2000 (2000-01-01), pages 3583-3587, XP002576926 *
BUKALEV VM ET AL: "Synthesis of 4,7-diamino-3-formylcoumarins and azomethines derived from them" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 29, no. 3, 1 January 1993 (1993-01-01), pages 282-291, XP002576923 *
CHECCHI S ET AL: "RICERCHE SPORA LA 4-IDROSSICUMARINA E DERIVATI. - NOTA IX. CLORURAZIONE DELLA 4-IDROSSICUMARINA E REAZIONI FRA 4-CLOROCUMARINA E COMPOSTI SODICI DI ESTERI E CHETONI AVENTI UN METILENE ATTIVO" GAZZETTA CHIMICA ITALIANA, SOCIETA CHIMICA, ITALIANA, ROME; IT, vol. 99, 1 January 1969 (1969-01-01), pages 501-513, XP009042561 ISSN: 0016-5603 *
HEBER D: "2.5-Dioxo-2H,5H-(1)-benzopyrano(4,3-b)pyr idine durch cyclisierung 3-substituierter 4-aminocumarine" ARCHIV DER PHARMAZIE, vol. 320, no. 7, 1 July 1987 (1987-07-01), pages 577-581, XP002576922 *
IVANOV IC ET AL: "Two method for the preparation of 3-dialkylaminomethyl derivatives (Mannich bases) of 4-aminocoumarin: a new type of intramolecular hydride transfer" SYNTHESIS, vol. 6, 1 January 1995 (1995-01-01), pages 633-634, XP002576919 *
KARANDASHOVA LA ET AL: "Basicity of 3-formyl-4,7-diaminocoumarins and their azomethine derivatives" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 29, no. 3, 1 January 1993 (1993-01-01), pages 292-294, XP002576925 *
KIRPICHENOK MA ET AL: "Reactions of 4-chloro-7-dialkylamino- and 3-alkyl-4-chloro-7-dialkylaminocoumarins with primary and secondary alkylamines" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 26, no. 26, 1 January 1990 (1990-01-01), pages 698-701, XP002576932 *
KIRPICHENOK MA ET AL: "Synthesis and spectral and luminescent properties of 3-formyl-7-dialkylaminocoumarins" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 27, no. 11, 1 January 1991 (1991-01-01), pages 1193-1199, XP002576921 *
KUROKI Y: "thermal ene reaction of 4-(2-alkenylamino)-3-formyl-2(2H)-chromeno nes" TETRAHEDRON, vol. 50, no. 4, 1 January 1994 (1994-01-01), pages 1063-1072, XP002576927 *
PRYANISHNIKOVA NT ET AL: "Synthesis and study of the pharmacological properties of 3,4-diaminocoumarins and 3-substituted 4-aminothiocoumarins" PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 12, no. 12, 1 January 1978 (1978-01-01), pages 1590-1593, XP002576928 *
SAVEL'EV VL ET AL: "Synthesis and pharmacological activity of 4H-(1)-benzopyrano(3,4-d)imidazol-4-ones" PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 17, no. 6, 1 January 1983 (1983-01-01), pages 423-425, XP002576924 *
SAVEL'EV VL ET AL: "Synthesis and study of the properties of 4-substituted 3-aminomethylcoumarins" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 18, no. 7, 1 January 1982 (1982-01-01), pages 676-679, XP002576920 *
SAVEL'EV: "N-(3-nitro(amino)coumarin-4-yl)antrhranil ic acid amides. Synthesis of 6, 7, 8, 13-tetrahydro(1)benzopyrano(4,3-b)(1,4)ben zodiazepine-6,8-dione" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 25, no. 9, 1 January 1989 (1989-01-01), pages 1011-1014, XP002576930 *
See also references of WO2007133211A1 *
STADLBAUER W ET AL: "SYNTHESE VON INDOLEN UND ISOCHINOLONEN AUS PHENYLMALONYLHETEROCYCLEN/ /SYNTHESIS OF INDOLES AND ISOQUINOLONES FROM PHENYLMALONATE HETEROCYCLES" MONATSHEFTE FUR CHEMIE, SPRINGER VERLAG WIEN, AT LNKD- DOI:10.1007/BF00810008, vol. 115, no. 4, 1 January 1984 (1984-01-01), pages 467-475, XP009049675 ISSN: 0026-9247 *
STADLBAUER W ET AL: "Isochinoline(4,3-c)chinolone aus phenylmalonylheterocyclen" MONATSHEFTE FÜR CHEMIE, vol. 113, 1 January 1982 (1982-01-01), pages 751-760, XP002576929 *
STEINFÜHRER T ET AL: "heterocyclisch (c)-anellierte Cumarine aus 4-Azido-3-cumarinecarbaldehyden" LIEBIGS ANNALEN DER CHEMIE, vol. 1, 1 January 1992 (1992-01-01), pages 23-28, XP002576931 *
TABAKOVIC K ET AL: "A novel transformation of 4-aylaminocoumarins to 6H-1-benzopyrano[4,3-b]quinolin-6-ones" SYNTHESIS, vol. 3, 1 January 1987 (1987-01-01), pages 308-310, XP002576918 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9877970B2 (en) 2013-02-15 2018-01-30 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10398703B2 (en) 2013-02-15 2019-09-03 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10966987B2 (en) 2013-02-15 2021-04-06 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
AU2006343604A1 (en) 2007-11-22
JP2009537518A (en) 2009-10-29
WO2007133211A1 (en) 2007-11-22
EP2028938A4 (en) 2010-07-07
CA2694955A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
US8048889B2 (en) 3,4-disubstituted coumarin and quinolone compounds
US7994360B2 (en) Benzofuran compounds
JP6506836B2 (en) Novel pyridazones and triazinones for the treatment and prevention of hepatitis B virus infection
WO2007133211A1 (en) 3,4-disubstituted coumarin and quinolone compounds
JP2019089792A (en) Azepane derivatives and methods of treating hepatitis b infections
JP4206382B2 (en) Substituted arylthioureas and related compounds; inhibitors of viral replication
EP1879575A2 (en) Thiazole compounds and methods of use
US7923004B2 (en) 4-ethynyl pyrazole derivative compounds and methods for treatment of HCV
EP1709047B1 (en) Azabenzofuran substituted thioureas as inhibitors of viral replication
Jia et al. Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors
US8329703B2 (en) Pyrazole compounds
JP2015531772A (en) Fused bicyclic sulfamoyl derivatives and their use as medicaments for the treatment of hepatitis B
US6608058B2 (en) 6-methylnicotinamide derivatives as antiviral agents
US8143276B2 (en) 4-thio substituted quinoline and naphthyridine compounds
WO2008024423A2 (en) 4-thio substituted quinoline and naphthyridine compounds
CN107074876B (en) Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and application thereof
CN112679489B (en) N-sulfonyl heterocyclic derivative and pharmaceutical use thereof
KR100661081B1 (en) 6-Methylnicotinamide derivatives as antiviral agents
WO2024149314A1 (en) Aminothiophene compound and preparation method therefor and use thereof
KR20040104824A (en) 2-[2-(4-Morpholino)ethylamino]pyridine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same
MXPA06007729A (en) Azabenzofuran substituted thioureas as inhibitors of viral replication

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LIU, YIXIN

Inventor name: SANDRASAGRA, ANTHONY

Inventor name: YANG, ZHEN

Inventor name: FATHI, REZA

Inventor name: CHO, HYUN-JOON

Inventor name: ZHU, QIANG

Inventor name: XU, BIN

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 311/56 20060101ALI20100525BHEP

Ipc: C07D 215/22 20060101ALI20100525BHEP

Ipc: A61K 31/44 20060101ALI20100525BHEP

Ipc: A01N 43/42 20060101AFI20080123BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100608

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111201